

Fill in this information to identify the case:

Debtor name Baudax Bio, Inc.

United States Bankruptcy Court for the: EASTERN DISTRICT OF PENNSYLVANIA

Case number (if known) 24-10583

☐ Check if this is an amended filing

Official Form 202

Declaration Under Penalty of Perjury for Non-Individual Debtors

12/15

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature

I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☒ *Schedule A/B: Assets—Real and Personal Property* (Official Form 206A/B)
- ☒ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☒ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☒ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☒ *Schedule H: Codebtors* (Official Form 206H)
- ☒ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ *Amended Schedule*
- ☐ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- ☐ Other document that requires a declaration

I declare under penalty of perjury that the foregoing is true and correct.

Executed on March 7, 2024

X /s/ Gerri Henwood

Signature of individual signing on behalf of debtor

Gerri Henwood

Printed name

Chief Executive Officer

Position or relationship to debtor

Fill in this information to identify the case:

Debtor name **Baudax Bio, Inc.**

United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**

Case number (if known) **24-10583**

☐ Check if this is an amended filing

Official Form 206Sum
Summary of Assets and Liabilities for Non-Individuals

12/15

Part 1: Summary of Assets

1. **Schedule A/B: Assets-Real and Personal Property** (Official Form 206A/B)

1a. Real property: Copy line 88 from <i>Schedule A/B</i>	\$ 0.00
1b. Total personal property: Copy line 91A from <i>Schedule A/B</i>	\$ 48,479.58
1c. Total of all property: Copy line 92 from <i>Schedule A/B</i>	\$ 48,479.58

Part 2: Summary of Liabilities

2. Schedule D: Creditors Who Have Claims Secured by Property (Official Form 206D) Copy the total dollar amount listed in Column A, <i>Amount of claim</i> , from line 3 of <i>Schedule D</i>	\$ 3,605,555.56
3. Schedule E/F: Creditors Who Have Unsecured Claims (Official Form 206E/F)	
3a. Total claim amounts of priority unsecured claims: Copy the total claims from Part 1 from line 5a of <i>Schedule E/F</i>	\$ 1,630,572.11
3b. Total amount of claims of nonpriority amount of unsecured claims: Copy the total of the amount of claims from Part 2 from line 5b of <i>Schedule E/F</i>	+\$ 10,995,246.45
4. Total liabilities Lines 2 + 3a + 3b	\$ 16,231,374.12

Fill in this information to identify the case:Debtor name **Baudax Bio, Inc.**United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**Case number (if known) **24-10583**☐ Check if this is an amended filing**Official Form 206A/B****Schedule A/B: Assets - Real and Personal Property**

12/15

Disclose all property, real and personal, which the debtor owns or in which the debtor has any other legal, equitable, or future interest. Include all property in which the debtor holds rights and powers exercisable for the debtor's own benefit. Also include assets and properties which have no book value, such as fully depreciated assets or assets that were not capitalized. In Schedule A/B, list any executory contracts or unexpired leases. Also list them on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G).

Be as complete and accurate as possible. If more space is needed, attach a separate sheet to this form. At the top of any pages added, write the debtor's name and case number (if known). Also identify the form and line number to which the additional information applies. If an additional sheet is attached, include the amounts from the attachment in the total for the pertinent part.

For Part 1 through Part 11, list each asset under the appropriate category or attach separate supporting schedules, such as a fixed asset schedule or depreciation schedule, that gives the details for each asset in a particular category. List each asset only once. In valuing the debtor's interest, do not deduct the value of secured claims. See the instructions to understand the terms used in this form.

Part 1: Cash and cash equivalents**1. Does the debtor have any cash or cash equivalents?**

- ☐ No. Go to Part 2.
☒ Yes Fill in the information below.

All cash or cash equivalents owned or controlled by the debtor**Current value of debtor's interest****3. Checking, savings, money market, or financial brokerage accounts (Identify all)**

Name of institution (bank or brokerage firm)

Type of account

Last 4 digits of account number

3.1. **PNC Bank****checking****8197****\$48,479.58**3.2. **PNC Bank****money market (acc't no. inaccessible)****\$0.00**3.3. **Capital Advisors/State Street Bank****investment account (acc't no. inaccessible)****\$0.00****4. Other cash equivalents (Identify all)****5. Total of Part 1.**

Add lines 2 through 4 (including amounts on any additional sheets). Copy the total to line 80.

\$48,479.58**Part 2: Deposits and Prepayments****6. Does the debtor have any deposits or prepayments?**

- ☒ No. Go to Part 3.
☐ Yes Fill in the information below.

Part 3: Accounts receivable**10. Does the debtor have any accounts receivable?**

Debtor **Baudax Bio, Inc.**
NameCase number (If known) **24-10583**

- ☒ No. Go to Part 4.
☐ Yes Fill in the information below.

Part 4: Investments**13. Does the debtor own any investments?**

- ☐ No. Go to Part 5.
☒ Yes Fill in the information below.

			Valuation method used for current value	Current value of debtor's interest
14.	Mutual funds or publicly traded stocks not included in Part 1 Name of fund or stock:			
15.	Non-publicly traded stock and interests in incorporated and unincorporated businesses, including any interest in an LLC, partnership, or joint venture Name of entity:	% of ownership		
15.1.	<u>Baudax Bio, Ltd. (f/k/a Recro Ireland Limited)</u>	<u>100</u> %		<u>\$0.00</u>
15.2.	<u>Teralmmune Therapeutics, Co., Ltd.</u>	<u>10</u> %		<u>\$0.00</u>
15.3.	<u>Teralmmune, LLC</u>	<u>100</u> %		<u>\$0.00</u>
15.4.	<u>Baudax Bio N.A. LLC</u>	<u>100</u> %		<u>\$0.00</u>
16.	Government bonds, corporate bonds, and other negotiable and non-negotiable instruments not included in Part 1 Describe:			
17.	Total of Part 4. Add lines 14 through 16. Copy the total to line 83.			<u>\$0.00</u>

Part 5: Inventory, excluding agriculture assets**18. Does the debtor own any inventory (excluding agriculture assets)?**

- ☐ No. Go to Part 6.
☒ Yes Fill in the information below.

	General description	Date of the last physical inventory	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
19.	Raw materials				
20.	Work in progress				
21.	Finished goods, including goods held for resale				
22.	Other inventory or supplies Expired viles of ANJESO (Meloxican)		<u>\$0.00</u>		<u>\$0.00</u>

Debtor **Baudax Bio, Inc.**
Name

Case number (If known) **24-10583**

23. **Total of Part 5.**

Add lines 19 through 22. Copy the total to line 84.

\$0.00

24. **Is any of the property listed in Part 5 perishable?**

- ☒ No
☐ Yes

25. **Has any of the property listed in Part 5 been purchased within 20 days before the bankruptcy was filed?**

- ☒ No
☐ Yes. Book value _____ Valuation method _____ Current Value _____

26. **Has any of the property listed in Part 5 been appraised by a professional within the last year?**

- ☒ No
☐ Yes

Part 6: Farming and fishing-related assets (other than titled motor vehicles and land)

27. **Does the debtor own or lease any farming and fishing-related assets (other than titled motor vehicles and land)?**

- ☒ No. Go to Part 7.
☐ Yes Fill in the information below.

Part 7: Office furniture, fixtures, and equipment; and collectibles

38. **Does the debtor own or lease any office furniture, fixtures, equipment, or collectibles?**

- ☐ No. Go to Part 8.
☒ Yes Fill in the information below.

General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
39. Office furniture MALVERN OFFICE: 28 desks, 12 office chairs, 5 conference tables, 4 training room tables, 8 training room chairs, 1 audio visual system (training room), 13 cubicles, 12 file cabinets, 1 refrigerator.	\$0.00		Unknown

40. **Office fixtures**

41. **Office equipment, including all computer equipment and communication systems equipment and software**

42. **Collectibles** *Examples:* Antiques and figurines; paintings, prints, or other artwork; books, pictures, or other art objects; china and crystal; stamp, coin, or baseball card collections; other collections, memorabilia, or collectibles

43. **Total of Part 7.**

Add lines 39 through 42. Copy the total to line 86.

\$0.00

44. **Is a depreciation schedule available for any of the property listed in Part 7?**

- ☒ No
☐ Yes

45. **Has any of the property listed in Part 7 been appraised by a professional within the last year?**

- ☒ No
☐ Yes

Debtor **Baudax Bio, Inc.**
Name

Case number (If known) **24-10583**

Part 8: Machinery, equipment, and vehicles

46. Does the debtor own or lease any machinery, equipment, or vehicles?

- ☐ No. Go to Part 9.
☒ Yes Fill in the information below.

	General description Include year, make, model, and identification numbers (i.e., VIN, HIN, or N-number)	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
47.	Automobiles, vans, trucks, motorcycles, trailers, and titled farm vehicles			
48.	Watercraft, trailers, motors, and related accessories <i>Examples: Boats, trailers, motors, floating homes, personal watercraft, and fishing vessels</i>			
49.	Aircraft and accessories			
50.	Other machinery, fixtures, and equipment (excluding farm machinery and equipment) 2 Toshiba copiers under lease	\$0.00		\$0.00

51. **Total of Part 8.**

Add lines 47 through 50. Copy the total to line 87.

\$0.00

52. **Is a depreciation schedule available for any of the property listed in Part 8?**

- ☒ No
☐ Yes

53. **Has any of the property listed in Part 8 been appraised by a professional within the last year?**

- ☒ No
☐ Yes

Part 9: Real property

54. Does the debtor own or lease any real property?

- ☐ No. Go to Part 10.
☒ Yes Fill in the information below.

55. **Any building, other improved real estate, or land which the debtor owns or in which the debtor has an interest**

	Description and location of property Include street address or other description such as Assessor Parcel Number (APN), and type of property (for example, acreage, factory, warehouse, apartment or office building, if available.	Nature and extent of debtor's interest in property	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
55.1.	Office Lease located at 420-500 Lapp Road, Suites 480 and 490, Malvern, PA 19355.		\$0.00		\$0.00

Debtor Baudax Bio, Inc. Case number (If known) 24-10583
Name

55.2. Office lease located
at 20400 Century
Boulevard, Suite 125,
Germantown, MD
20874. \$0.00 \$0.00

56. Total of Part 9. \$0.00
Add the current value on lines 55.1 through 55.6 and entries from any additional sheets.
Copy the total to line 88.

57. Is a depreciation schedule available for any of the property listed in Part 9?

☒ No
☐ Yes

58. Has any of the property listed in Part 9 been appraised by a professional within the last year?

☒ No
☐ Yes

Part 10: Intangibles and intellectual property

59. Does the debtor have any interests in intangibles or intellectual property?

☐ No. Go to Part 11.
☒ Yes Fill in the information below.

	General description	Net book value of debtor's interest (Where available)	Valuation method used for current value	Current value of debtor's interest
60.	Patents, copyrights, trademarks, and trade secrets Various patents; a list of the Debtor's intellectual property portfolio is attached.	<u>\$0.00</u>		<u>Unknown</u>
61.	Internet domain names and websites <u>www.baudaxbio.com</u>	<u>\$0.00</u>		<u>Unknown</u>
62.	Licenses, franchises, and royalties Various patent agreements and licenses; a list of the Debtor's intellectual property portfolio is attached.	<u>\$0.00</u>		<u>Unknown</u>
63.	Customer lists, mailing lists, or other compilations			
64.	Other intangibles, or intellectual property			
65.	Goodwill Business goodwill	<u>\$0.00</u>		<u>Unknown</u>

66. Total of Part 10. \$0.00
Add lines 60 through 65. Copy the total to line 89.

67. Do your lists or records include personally identifiable information of customers (as defined in 11 U.S.C. §§ 101(41A) and 107?

☒ No
☐ Yes

Debtor **Baudax Bio, Inc.** Case number (If known) **24-10583**
Name

68. Is there an amortization or other similar schedule available for any of the property listed in Part 10?

- ☒ No
☐ Yes

69. Has any of the property listed in Part 10 been appraised by a professional within the last year?

- ☒ No
☐ Yes

Part 11: All other assets

70. Does the debtor own any other assets that have not yet been reported on this form?

Include all interests in executory contracts and unexpired leases not previously reported on this form.

- ☐ No. Go to Part 12.
☒ Yes Fill in the information below.

Current value of
debtor's interest

71. Notes receivable

Description (include name of obligor)

Note receivable from Baudax Bio, Ltd.

0.00
Total face amount

- 0.00
doubtful or uncollectible amount

\$0.00

72. Tax refunds and unused net operating losses (NOLs)

Description (for example, federal, state, local)

73. Interests in insurance policies or annuities

Director and officer insurance policy; other commercial policies

\$0.00

74. Causes of action against third parties (whether or not a lawsuit has been filed)

75. Other contingent and unliquidated claims or causes of action of every nature, including counterclaims of the debtor and rights to set off claims

76. Trusts, equitable or future interests in property

77. Other property of any kind not already listed Examples: Season tickets, country club membership

78. Total of Part 11.

Add lines 71 through 77. Copy the total to line 90.

\$0.00

79. Has any of the property listed in Part 11 been appraised by a professional within the last year?

- ☒ No
☐ Yes

Debtor **Baudax Bio, Inc.**
Name

Case number (If known) **24-10583**

Part 12: Summary

In Part 12 copy all of the totals from the earlier parts of the form

Type of property	Current value of personal property	Current value of real property
80. Cash, cash equivalents, and financial assets. <i>Copy line 5, Part 1</i>	\$48,479.58	
81. Deposits and prepayments. <i>Copy line 9, Part 2.</i>	\$0.00	
82. Accounts receivable. <i>Copy line 12, Part 3.</i>	\$0.00	
83. Investments. <i>Copy line 17, Part 4.</i>	\$0.00	
84. Inventory. <i>Copy line 23, Part 5.</i>	\$0.00	
85. Farming and fishing-related assets. <i>Copy line 33, Part 6.</i>	\$0.00	
86. Office furniture, fixtures, and equipment; and collectibles. <i>Copy line 43, Part 7.</i>	\$0.00	
87. Machinery, equipment, and vehicles. <i>Copy line 51, Part 8.</i>	\$0.00	
88. Real property. <i>Copy line 56, Part 9.....></i>		\$0.00
89. Intangibles and intellectual property. <i>Copy line 66, Part 10.</i>	\$0.00	
90. All other assets. <i>Copy line 78, Part 11.</i>	+ \$0.00	
91. Total. Add lines 80 through 90 for each column	\$48,479.58	+ 91b. \$0.00
92. Total of all property on Schedule A/B. Add lines 91a+91b=92		\$48,479.58

Baudax Bio Intellectual Property Portfolio

Reference #	Country Name	Assignee Name	Title	Serial #	Filed Date	Publication #	Publication Date	Patent #	Issue Date	Status
148428-000100	UNITED STATES	BAUDAX BIO, INC.	SUBLINGUAL DEXMEDETOMIDINE SPRAY COMPOSITIONS AND METHODS OF USE THEREOF	61/178,730	5/15/2009					EXPIRED
148428-000101	UNITED STATES	BAUDAX BIO, INC.	ORAL MUCOSAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12/781,628	5/17/2010	2011-0021588	1/27/2011			ABANDONED
148428-000102	WIPO	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	PCT/US2010/035136	5/17/2010	2010/132882	11/18/2010			NAT PHASE
148428-000103	EUROPE	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10775671.0	5/17/2010	2429521	3/21/2012	2429521	10/18/2017	ISSUED
148428-000104	JAPAN	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2012-511068	5/17/2010	2012-526854	11/1/2012	6172938	7/14/2017	TO ABAND
148428-000106	MEXICO	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	MX/a/2011/011950	5/17/2010	MX/a/2011/011950	2/21/2012	333985	10/13/2015	TO ABAND
148428-000107	AUSTRALIA	Baudax Bio, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2010248776	5/17/2010	2010248776	1/12/2012	2010248776	9/19/2013	TO ABAND
148428-000109	SOUTH KOREA	RECROPHARMA, INC.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10-2011-7027466	5/17/2010	10-2011-7027466	1/25/2012	1018594860000	5/14/2018	TO ABAND
148428-000111	UNITED STATES		ORAL MUCOSAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	15/424923	2/6/2017					Abandoned
148428-000115	RUSSIA	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2011151059	5/17/2010	2011151059	6/20/2013	2572692	12/14/2015	ABANDONED
148428-000117	ISRAEL	Baudax Bio, Inc.	ORAL TRANSMUCOSAL DEXMEDETOMIDINE COMPOSITIONS, DELIVERY DEVICE COMPRISING THE SAME AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING PAIN WITHOUT SEDATION	216159	5/17/2010	216159	2/3/2013	216159	1/30/2016	TO ABAND
148428-000119	NEW ZEALAND	Baudax Bio, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	596976	5/17/2010	596976	5/30/2014	596976	9/2/2014	TO ABAND
148428-000123	HONG KONG	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12109245.0	5/17/2010	1168302	12/28/2012	1168302	5/4/2018	ABANDONED
148428-000126	SOUTH AFRICA		SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2011/08359	5/17/2010			2011/08359	7/25/2012	TO ABAND
148428-000127	SINGAPORE	Baudax Bio, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2011082666	5/17/2010	175979	12/29/2011	175979	9/23/2014	TO ABAND
148428-000128	GERMANY	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10775671.0	5/17/2010	2429521	3/21/2012	602010046063.0	10/18/2017	ABANDONED
148428-000129	FRANCE	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10775671.0	5/17/2010	2429521	3/21/2012	2429521	10/18/2017	TO ABAND
148428-000133	UNITED KINGDOM	Baudax Bio, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10775671.0	5/17/2010	2429521	3/21/2012	2429521	10/18/2017	TO ABAND
148428-000134	IRELAND	Recro Pharma, Inc.	SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10775671.0	5/17/2010	2429521	3/21/2012	2429521	10/18/2017	TO ABAND
148428-000200	UNITED STATES		TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	61/293440	1/8/2010					Expired
148428-000201	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	13/520959	12/3/2012	2013-0072532	3/21/2013			Abandoned
148428-000202	WIPO	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	PCT/US2011/020462	1/7/2011	2011/085162	7/14/2011			NAT PHASE
148428-000203	EUROPE	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	11732180.2	1/7/2011	2521544	11/14/2012			Abandoned
148428-000204	JAPAN		TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2012-548137	1/7/2011	2013-516482	5/13/2013			Abandoned
148428-000205	CANADA	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2786598	1/7/2011	2786598	7/14/2011			ABANDONED
148428-000206	MEXICO	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	MX/a/2012/007933	1/7/2011	MX2012007933A	8/15/2012			Abandoned
148428-000207	AUSTRALIA	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2011204315	1/7/2011	2011204315	7/14/2011			LAPSED
148428-000208	CHINA	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	201180008886.9	1/7/2011	102753169	10/24/2012			Abandoned
148428-000209	NEW ZEALAND	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	601195	1/7/2011	601195	2/27/2015	601195	5/28/2015	Abandoned
148428-000213	HONG KONG	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	13105662.1	1/7/2011	1177894	8/30/2013			Abandoned
148428-000214	RUSSIA	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2012133969	1/7/2011	2012133969	2/20/2014			Abandoned
148428-000215	GERMANY		TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	N/A	1/7/2011					Abandoned
148428-000219	NEW ZEALAND	Recro Pharma, Inc.	TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	703808	1/7/2011	703808	1/29/2016	703808	5/3/2016	Abandoned
148428-000300	UNITED STATES		BACK PAIN	61/466191	3/22/2011					Expired
148428-000400	UNITED STATES		INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	61/569,255	12/11/2011					Expired
148428-000401	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	13/711,407	12/11/2012	2013-0178465	7/11/2013	9795559	10/24/2017	ISSUED
148428-000402	WIPO	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	PCT/US2012/068988	12/11/2012	2013/090278	6/20/2013			NAT PHASE
148428-000403	EUROPE	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	2787970	4/11/2018	ABANDONED
148428-000404	JAPAN	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2014-546186	12/11/2012	2015-513309	5/7/2015	6268100	1/5/2018	ABANDONED
148428-000405	CANADA	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2858721	12/11/2012	2858721	6/20/2013	2858721	3/16/2021	ABANDONED
148428-000406	SINGAPORE	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	11201403094T	12/11/2012	11201403094T	10/30/2014			Abandoned
148428-000407	AUSTRALIA	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2012352528	12/11/2012	2012352528	7/10/2014	2012352528	2/8/2018	ABANDONED
148428-000408	AUSTRIA	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	987264	4/11/2018	Abandoned
148428-000409	SOUTH KOREA	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10-2014-7017624	12/11/2012	10-2014-7017624		1021900090000	12/7/2020	ABANDONED
148428-000411	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	15/702,319	9/12/2017	2018-0055764	3/1/2018	10,682,311	6/16/2020	ISSUED
148428-000413	EUROPE	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	18161834.9	12/11/2012	3406247	11/28/2018			Abandoned
148428-000414	JAPAN	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2017-172633	12/11/2012	2018-030850	3/1/2018	6505177	4/5/2019	ABANDONED

148428-000415	MEXICO	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	MX/a/2014/006961	12/11/2012	MX2014006961A	9/22/2014	367286	8/13/2019	ABANDONED
148428-000416	BRAZIL	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	1120140191719	12/11/2012	1120140191719	6/20/2017			ABANDONED
148428-000417	AUSTRALIA	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2018200591	12/11/2012	2018200591	2/15/2018	2018200591	3/14/2019	ABANDONED
148428-000418	NEW ZEALAND	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	626999	12/11/2012	626999	7/29/2016	626999	11/1/2016	ABANDONED
148428-000419	ISRAEL	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	232977	12/11/2012	232977	7/31/2014	232977	5/1/2019	ABANDONED
148428-000423	HONG KONG	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	15103572.3	12/11/2012	1203049	10/16/2015	1203049	5/17/2019	ABANDONED
148428-000424	INDIA	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	5403/DELNP/2014	12/11/2012	5403/DELNP/2014	3/27/2015			TO ABAND
148428-000425	RUSSIA	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2014128343	12/11/2012	2014128343	1/27/2016	2692245	6/24/2019	ABANDONED
148428-000426	SOUTH AFRICA	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	2014/04287	12/11/2012					ABANDONED
148428-000427	EGYPT	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	916/2014 PCT	12/11/2012					ABANDONED
148428-000428	GERMANY	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	602012045177.7	4/11/2018	ABANDONED
148428-000429	FRANCE	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	2787970	4/11/2018	ABANDONED
148428-000433	UNITED KINGDOM	Baudax Bio, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	2787970	4/11/2018	ABANDONED
148428-000434	IRELAND	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	2787970	4/11/2018	ABANDONED
148428-000435	ITALY	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	12857098.3	12/11/2012	2787970	10/15/2014	2787970	4/11/2018	ABANDONED
148428-000436	SINGAPORE	Recro Pharma, Inc.	INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	10201604653T	12/11/2012	10201604653T	7/28/2016			Abandoned
148428-000437	PHILIPPINES		INTRANASAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF	1/2014/501273	12/11/2012	1/2014/501273	9/8/2014			Abandoned
148428-000500	UNITED STATES		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	60/162120	10/29/1999					Expired
148428-000501	UNITED STATES	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	10/111628	8/23/2002					Abandoned
148428-000502	WIPO	Orion Corporation and Cygnus Therapeutics Systems	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	PCT/FI2000/000935	10/27/2000	2001/030347	5/3/2001			NAT PHASE
148428-000503	EUROPE	Orion Corporation and Cygnus Therapeutics Systems	USE OF A IMIDAZOLE DERIVATIVE FOR THE TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	00972934.4	10/27/2000	1223931	7/24/2002	1223931	12/14/2005	Expired
148428-000504	JAPAN		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	2001-532767	10/27/2000	2003-527333	9/16/2003	4741131	5/13/2011	Expired
148428-000505	CANADA	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	2388979	10/27/2000	2388979	5/3/2001	2388979	9/14/2010	Expired
148428-000506	RUSSIA	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	2002113918	10/27/2000	2002113918	12/20/2003	2259827	9/10/2005	Expired
148428-000507	AUSTRALIA	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	11492/01	10/27/2000	11492/01	7/26/2001	778522	4/14/2005	Expired
148428-000508	NORWAY	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	20021920	10/27/2000			329889	1/17/2011	EXPIRED
148428-000509	NEW ZEALAND	ORION CORPORATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	518447	10/27/2000	518447	10/29/2004	518447	10/2/2005	Expired
148428-000511	UNITED STATES		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	11/641953	12/20/2006	2007-0185181	8/9/2007			Abandoned
148428-000521	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	13/096387	4/28/2011	2011-0294862	12/1/2011	8470862	6/25/2013	Expired
148428-000531	UNITED STATES		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	13/925271	6/24/2013	2014-0100257	4/10/2014	9078883	7/14/2015	EXPIRED
148428-000541	UNITED STATES		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	14/738717	6/12/2015	2016-0030392	2/4/2016	9446025	9/20/2016	EXPIRED
148428-000551	UNITED STATES		TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK	15/239227	8/17/2016					Abandoned
148428-000600	FINLAND		NEW PHARMACEUTICAL COMPOUNDS	20022159	12/5/2002					Abandoned
148428-000601	UNITED STATES	Baudax Bio, Inc.	IMIDAZOL DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY	10/537,622	3/29/2006	2006-0178417	8/10/2006	7759496	7/20/2010	ISSUED
148428-000602	WIPO	ORION CORPORATION	IMIDAZOL DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY	PCT/FI2003/000933	12/5/2003	2004/050635	6/17/2004			Expired
148428-000603	EUROPE	Orion Corporation and Cygnus Therapeutics Systems	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	9/14/2005	1572198	4/19/2006	EXPIRED
148428-000604	JAPAN	ORION CORPORATION	PHARMACEUTICAL COMPOUNDS	2004-556387	12/5/2003	2006-509780	3/23/2006	4667042	1/21/2011	ABANDONED
148428-000605	CANADA	ORION CORPORATION	IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY	2508335	12/5/2003	2508335	6/17/2004	2508335	9/13/2011	EXPIRED
148428-000608	CHINA	Orion Oyj	IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA 2 RECEPTORS ACTIVITY	200380105132.0	12/5/2003	1735409	2/15/2006	1735409	11/18/2009	EXPIRED
148428-000613	GERMANY	ORION CORPORATION	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	6/17/2004	60304741.6	4/19/2006	EXPIRED
148428-000614	SPAIN	ORION CORPORATION	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	6/17/2004	2262031	4/19/2006	EXPIRED
148428-000615	FRANCE	ORION CORPORATION	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	6/17/2004	1572198	4/19/2006	EXPIRED
148428-000616	UNITED KINGDOM	ORION CORPORATION	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	9/14/2005	1572198	4/19/2006	EXPIRED
148428-000617	IRELAND	ORION CORPORATION	NEW PHARMACEUTICAL COMPOUNDS WITH ALPHA2RECEPTOR ACTIVITY	03812203.2	12/5/2003	1572198	6/17/2004	1572198	4/19/2006	EXPIRED
148428-000700	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION- INDUCED ADVERSE PHYSIOLOGICAL REACTIONS	60/004488	9/29/1995					Expired
148428-000701	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION- INDUCED ADVERSE PHYSIOLOGICAL REACTIONS	08/696754	8/14/1996			5834025	11/10/1998	Expired
148428-000702	WIPO	NANOSYSTEMS L.L.C.	REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE	PCT/US1996/015300	9/25/1996	1997/11686	4/3/1997			NAT PHASE
148428-000711	UNITED STATES		REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS	12/027100	2/6/2008			RE41884	10/26/2010	Expired

148428-000800	UNITED STATES		COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	60/328405	10/12/2001				Expired
148428-000801	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP Baudax Bio, Inc.	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	10/268,928	10/11/2002	2003-0137067	7/24/2003	6908626	6/21/2005 EXPIRED
148428-000802	WIPO	Elan Pharma International Ltd.	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	PCT/US2002/032314	10/11/2002	2003/030872	4/17/2003		NAT PHASE
148428-000803	EUROPE	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	4/17/2003	1443912	8/29/2007 EXPIRED
148428-000804	JAPAN		COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE	2003-533905	10/11/2002	2005-508939	4/7/2005		Abandoned
148428-000805	CANADA	ELAN PHARMA INTERNATIONAL, LTD.	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	2463495	10/11/2002	2463495	4/17/2003	2463495	5/24/2011 EXPIRED
148428-000814	FRANCE	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000815	GERMANY	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000816	SPAIN	Elan Pharma International Ltd.	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000817	IRELAND	Elan Pharma International Ltd.	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000818	ITALY	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000819	UNITED KINGDOM	DV Technology LLC	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	02800993.4	10/11/2002	1443912	8/11/2004	1443912	8/29/2007 EXPIRED
148428-000824	JAPAN	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE	2009-024799	10/11/2002	2010-047599	3/4/2010		Abandoned
148428-000834	JAPAN	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	2013-126534	10/11/2002	2013-209422	10/10/2013		Abandoned
148428-000844	JAPAN	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE CHARACTERISTICS	2015-043408	10/11/2002	2015-108022	6/11/2015		Abandoned
148428-000854	JAPAN	Elan Pharma International Limited	COMPOSITIONS HAVING A COMBINATION OF IMMEDIATE RELEASE AND CONTROLLED RELEASE PROPERTIES	2017-017261	10/11/2002	2017-075182	4/20/2017		Abandoned
148428-000900	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	60/353230	2/4/2002				TRANSFER
148428-000901	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	10/357514	2/4/2003	2003-0185869	10/2/2003	7459283	12/2/2008 TRANSFER
148428-000902	WIPO	ELAN PHARMA INTERNATIONAL, LTD.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	PCT/US2003/001083	2/4/2003	2003/066021	8/14/2003		TRANSFER
148428-000903	EUROPE	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000904	JAPAN	Elan Pharma International Limited	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	2003-565446	2/4/2003	2005-523900	8/11/2005	4598399	10/1/2010 TRANSFER
148428-000905	CANADA	ELAN PHARMA INTERNATIONAL, LTD.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	2475092	2/4/2003	2475092	8/14/2003	2475092	5/1/2012 TRANSFER
148428-000911	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	12/292091	11/12/2008	2009-0074875	3/19/2009	8323641	12/4/2012 TRANSFER
148428-000921	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	13/693,858	12/4/2012	2013-0224123	8/29/2013	8652464	2/18/2014 TRANSFER
148428-000923	BELGIUM	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000924	DENMARK	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000925	FINLAND	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000926	FRANCE	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000927	GERMANY	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	60332212.3	4/21/2010 TRANSFER
148428-000928	HUNGARY	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000929	IRELAND	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000931	UNITED STATES	RECRO GAINESVILLE LLC (F/K/A RECRO TECHNOLOGY LLC)	METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	14/182097	2/17/2014	2014-0234225	8/21/2014		TRANSFER
148428-000933	ITALY	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	502010901854570	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000934	NETHERLANDS	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000935	SPAIN	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	2343405	4/21/2010 TRANSFER
148428-000936	SWEDEN	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000937	SWITZERLAND	Elan Pharma International Ltd.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-000938	UNITED KINGDOM	Baudax Bio, Inc.	NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER	03737537.5	2/4/2003	1471887	11/3/2004	1471887	4/21/2010 TRANSFER
148428-001000	UNITED STATES		NANOPARTICULATE MELOXICAM FORMULATIONS	60/450705	3/3/2003				TRANSFER
148428-00100108	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	Nanoparticulate meloxicam formulations	10/784,900	2/24/2004	2004-0229038	11/18/2004	8,512,727	8/20/2013 TRANSFER
148428-001002	WIPO	Elan Pharma International Ltd.	NANOPARTICULATE MELOXICAM FORMULATIONS	PCT/US2004/005706	2/27/2004	2005/002542	1/13/2005		TRANSFER
148428-001003	EUROPE	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009 TRANSFER
148428-001004	JAPAN		THE NANOPARTICULATE MELOXICAM FORMULATIONS	2006-532300	2/27/2004	2007-505154	3/8/2007	4891774	12/22/2011 TRANSFER

148428-001005	CANADA	Elan Pharma International Ltd.	NANOPARTICULATE MELOXICAM FORMULATIONS	2517679	2/27/2004	2517679	1/13/2005	2517679	4/10/2012	TRANSFER
148428-001011	UNITED STATES	ALKERMES CONTROLLED THERAPEUTICS INC.	NANOPARTICULATE MELOXICAM FORMULATIONS	12/788203	5/26/2010	2010-0297252	11/25/2010			TRANSFER
148428-001013	EUROPE	DV Technology LLC	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	08006465.2	2/27/2004	1938803	7/2/2008			TRANSFER
148428-001014	JAPAN	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	2010-233858	2/27/2004	2011-042670	3/3/2011	5548092	5/23/2014	TRANSFER
148428-001015	BELGIUM	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001016	FRANCE	ELAN PHARMA INTERNATIONAL, LTD.	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001017	GERMANY	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	602004021107.9	5/13/2009	TRANSFER
148428-001018	HUNGARY		NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	E005977	5/13/2009	TRANSFER
148428-001019	IRELAND	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001021	UNITED STATES	Baudax Bio, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	13/941076	7/12/2013	2014-0141083	5/22/2014			TRANSFER
148428-001023	EUROPE	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001024	JAPAN	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATION	2011-148037	2/27/2004	2012-012397	1/19/2012			TRANSFER
148428-001025	ITALY	BAUDAX BIO, INC.	NANOPARTICULATE MELOXICAM FORMULATIONS	502009901749875	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001026	SPAIN	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001027	SWITZERLAND	Elan Pharma International Limited	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001028	UNITED KINGDOM	Baudax Bio, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	04785761.0	2/27/2004	1617816	1/25/2006	1617816	5/13/2009	TRANSFER
148428-001029	AUSTRIA	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	2016161176	9/19/2018	TRANSFER
148428-0010310B	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	NANOPARTICULATE MELOXICAM FORMULATIONS	15/437,534	2/21/2017	2017-0157061	6/8/2017	10,471,067	11/12/2019	TRANSFER
148428-001033	EUROPE	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001034	BELGIUM	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001035	SWITZERLAND	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001036	GERMANY	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	602004053216.9	9/19/2018	TRANSFER
148428-001037	DENMARK	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001038	SPAIN	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	2701673	9/19/2018	TRANSFER
148428-001039	FINLAND	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-0010410B	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	NANOPARTICULATE MELOXICAM FORMULATIONS	15/950,367	4/11/2018	2018-0228809	8/16/2018	10463673	11/5/2019	TRANSFER
148428-001043	FRANCE	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001044	UNITED KINGDOM	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001045	HUNGARY	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001046	IRELAND	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001047	ITALY	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	502018000038849	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001048	NETHERLANDS	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001049	SWEDEN	Recro Pharma, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	16161176.9	2/27/2004	3090731	11/9/2016	3090731	9/19/2018	TRANSFER
148428-001051	UNITED STATES	Baudax Bio, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	15/950539	4/11/2018	2018-0228810	8/16/2018			TRANSFER
148428-001053	HONG KONG	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	17102503.7	2/27/2004	1228765	11/10/2017	1228765	10/11/2019	TRANSFER
148428-001054	HONG KONG	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	19127168.3	2/27/2004	40003692	4/17/2020	40003692	5/28/2021	TRANSFER
148428-001055	AUSTRIA	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	2018186018	10/28/2020	TRANSFER
148428-001056	BELGIUM	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004			3434261	10/28/2020	TRANSFER
148428-001057	SWITZERLAND	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001058	GERMANY	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	60 2004 054 850.2	10/28/2020	TRANSFER
148428-001059	DENMARK	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001061	UNITED STATES	Baudax Bio, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	16/507796	7/10/2019	2020-0155564	5/21/2020			TRANSFER
148428-001064	SPAIN	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004			3434261	10/28/2020	TRANSFER
148428-001065	FINLAND	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001066	FRANCE	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004			3434261	10/28/2020	TRANSFER
148428-001067	UNITED KINGDOM	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001068	HUNGARY	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004			3434261	10/28/2020	TRANSFER
148428-001069	IRELAND	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001071	UNITED STATES	Recro Pharma, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	16/550,239	8/25/2019	2019-0381062	12/19/2019	10709713	7/14/2020	TRANSFER
148428-001075	NETHERLANDS	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001076	SWEDEN	Baudax Bio, Inc.	FORMULATIONS COMPRISING NANOPARTICULATE MELOXICAM	18186018.0	2/27/2004	3434261	1/30/2019	3434261	10/28/2020	TRANSFER
148428-001081	UNITED STATES	Baudax Bio, Inc.	NANOPARTICULATE MELOXICAM FORMULATIONS	16/894,247	6/5/2020	2021-0113580	4/22/2021			TRANSFER
148428-001091	UNITED STATES		NANOPARTICULATE MELOXICAM FORMULATIONS	17/807,576	6/17/2022					TRANSFER
148428-001100	UNITED STATES		METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	62/640232	3/8/2018					TRANSFER

148428-001101	UNITED STATES	Baudax Bio, Inc.	METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	16/297,020	3/8/2019	2019-0275053	9/12/2019	10,881,663	1/5/2021	TRANSFER
148428-001111	UNITED STATES		METHOD OF TREATING PAIN IN ELDERLY PATIENTS WITH MILD RENAL IMPAIRMENT	17/125042	12/17/2020					TRANSFER
148428-001200	UNITED STATES		METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	62/652656	4/4/2018					TRANSFER
148428-001201	UNITED STATES	WILMINGTON TRUST, NATIONAL ASSOCIATION	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	16/297,095	3/8/2019	2019-0275054	9/12/2019	11,458,145	10/4/2022	TRANSFER
148428-001202	WIPO	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	PCT/US2019/021354	3/8/2019	2019/173715	9/12/2019			TRANSFER
148428-001203	EUROPE	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	19764737.3	3/8/2019	3761977	1/13/2021			TRANSFER
148428-001204	JAPAN	Bow DAX Biotechnology Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	2020-571332	3/8/2019	2021-527697	10/14/2021			TRANSFER
148428-001205	CANADA		METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE							NOT FILED
148428-001206	NEW ZEALAND	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	767981	3/8/2019					TRANSFER
148428-001207	AUSTRALIA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	2019231858	3/8/2019					TRANSFER
148428-001208	CHINA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	201980004945.1	3/8/2019	111201020	5/26/2020			TRANSFER
148428-001209	SOUTH KOREA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	10-2020-7027716	3/8/2019	10-2020-0130334	11/18/2020			TRANSFER
148428-001211	UNITED STATES	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	17/820,783	8/18/2022					TRANSFER
148428-001218	HONG KONG	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE	62020020480.3	3/8/2019	40032144	3/19/2021			TRANSFER
148428-001300	UNITED STATES		METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	62/749407	10/23/2018					TRANSFER
148428-001301	UNITED STATES	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	17/287,489	4/21/2021	2021-0386753	12/16/2021			TRANSFER
148428-001302	WIPO	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	PCT/US2019/057692	10/23/2019	2020/086737	4/30/2020			TRANSFER
148428-001303	EUROPE	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	19876037.3	10/23/2019	3870163	9/1/2021			TRANSFER
148428-001304	JAPAN	Bow DAX Biotechnology Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	2021-521960	10/23/2019	2022-505572	1/14/2022			TRANSFER
148428-001305	CANADA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	3117209	10/23/2019	3117209	4/30/2020			TRANSFER
148428-001306	NEW ZEALAND	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	775856	10/23/2019					TRANSFER
148428-001307	AUSTRALIA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	2019364416	10/23/2019					TRANSFER
148428-001308	CHINA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	201980004887.2	10/23/2019	111356453	6/30/2020			TRANSFER
148428-001309	SOUTH KOREA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	10-2021-7013779	10/23/2019	10-2021-0081354	7/1/2021			TRANSFER
148428-001315	RUSSIA	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	2021114360	10/23/2019	2021114360	11/24/2022			TRANSFER
148428-001318	HONG KONG	Baudax Bio, Inc.	METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS	62020021461.2	10/23/2019	40031604	3/12/2021			TRANSFER
148428-001400	UNITED STATES		HIGHLY CONCENTRATED MELOXICAM FORMULATIONS	62/703094						TRANSFER
148428-001500	UNITED STATES	Baudax Bio, Inc.	METHOD OF TREATING PATIENTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	62/757003	11/7/2018					TRANSFER
148428-001501	UNITED STATES	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	17/292,403	5/7/2021	2022-0008430	1/13/2022			TRANSFER
148428-001502	WIPO	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	PCT/US2019/060278	11/7/2019	2020/097338	5/14/2020			TRANSFER
148428-001503	EUROPE	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	19881104.4	11/7/2019	3876910	9/15/2021			TRANSFER
148428-001504	JAPAN	Bow DAX Biotechnology Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	2021-524241	11/7/2019	2022-506696	1/17/2022			TRANSFER
148428-001505	CANADA	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	3118952	11/7/2019	3118952	5/14/2020			TRANSFER
148428-001506	NEW ZEALAND	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	776380	11/7/2019					TRANSFER
148428-001507	AUSTRALIA	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	2019374827	11/7/2019					TRANSFER
148428-001508	CHINA	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	201980004883.4	11/7/2019	111565713	8/21/2020			TRANSFER
148428-001509	SOUTH KOREA	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	10-2021-7015337	11/7/2019	10-2021-0089175	7/15/2021			TRANSFER
148428-001515	RUSSIA	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	2021116051	11/7/2019	2021116051	12/7/2022			TRANSFER
148428-001518	HONG KONG	Baudax Bio, Inc.	METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAM	62021024238.9	11/7/2019	40034393	4/23/2021			TRANSFER
148428-001600-S	UNITED STATES		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	61/181641	5/27/2009					Expired
148428-001601-S	UNITED STATES		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	12/788196	5/26/2010	2010-0316725	12/16/2010			Abandoned
148428-001602-S	WIPO	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	PCT/US2010/036127	5/26/2010	2010/138539	12/2/2010			INACTIVE
148428-001603-S	EUROPE	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE

148428-001604-S	JAPAN	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2012-513185	5/26/2010	2012-528171	11/12/2012	6072539	1/13/2017	INACTIVE
148428-001605-S	CANADA	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2763456	5/26/2010	2763456	12/2/2010	2763456	10/24/2017	INACTIVE
148428-001606-S	TAIWAN		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	099116808	5/26/2010	201043264	11/21/2016	558422	11/21/2016	INACTIVE
148428-001607-S	AUSTRALIA	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2010254180	5/26/2010	2010254180	12/2/2010	2010254180	12/10/2015	INACTIVE
148428-001611-S	UNITED STATES	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	14/133191	12/18/2013	2014-0105984	4/17/2014	9345665	5/24/2016	INACTIVE
148428-001613-S	EUROPE	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	16189936.4	5/26/2010	3167875	5/17/2017			INACTIVE
148428-001614-S	JAPAN	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2015-185009	5/26/2010	2016-053028	4/14/2016	6694682	4/22/2020	INACTIVE
148428-001615-S	BELGIUM	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001616-S	FRANCE	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001617-S	GERMANY	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	602010036932.3	10/5/2016	INACTIVE
148428-001618-S	HUNGARY	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001619-S	IRELAND	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001621-S OB	UNITED STATES	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	15/130255	4/15/2016	2016-0228554	8/11/2016	9974746	5/22/2018	INACTIVE
148428-001623-S	HONG KONG	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	17108657.8	5/26/2010	1235663	3/16/2018			INACTIVE
148428-001624-S	JAPAN	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2018-076691	5/26/2010	2018-138567	9/6/2018			Abandoned
148428-001625-S	ITALY	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	502016000125561	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001626-S	SPAIN	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2609415	10/5/2016	INACTIVE
148428-001627-S	SWITZERLAND	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001628-S	UNITED KINGDOM	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE MELOXICAM COMPOSITIONS	10728470.5	5/26/2010	2435027	4/4/2012	2435027	10/5/2016	INACTIVE
148428-001631-S	UNITED STATES	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	15/130331	4/15/2016	2016-0228555	8/11/2016	9974747	5/22/2018	INACTIVE
148428-001634	JAPAN		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2020-080258	5/26/2010	2020-125345	8/20/2020			INACTIVE
148428-001641-S	UNITED STATES	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	15/130396	4/15/2016	2016-0228372	8/11/2016	9974748	5/22/2018	INACTIVE
148428-001644	JAPAN		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	2022-100384	6/23/2022	2022-126786	8/30/2022			INACTIVE
148428-001651-S	UNITED STATES	Alkermes Pharma Ireland Limited	REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	15/971616	5/4/2018	2018-0250229	9/6/2018	11253478	2/22/2022	INACTIVE
148428-001661-S	UNITED STATES		REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS	17/542,276	12/3/2021	2022-0211626	7/7/2022			INACTIVE
148428-001700-S	MALAYSIA	NANOSYSTEMS L.L.C.	CONTINUOUS METHOD OF GRINDING PHARMACEUTICAL SUBSTANCES	P195001375	5/25/1995			MY-113569-A	4/30/2002	Expired
148428-001800-S	UNITED STATES		SMALL SCALE HIGH ENERGY MILL AND METHOD THEREOF	60/137142	6/1/1999					Expired
148428-001801-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	SMALL SCALE HIGH ENERGY MILL AND METHOD THEREOF	09/583893	5/31/2000			6431478	8/13/2002	Expired
148428-001802-S	WIPO	Elan Pharma International Ltd.	SMALL-SCALE MILL AND METHOD THEREOF	PCT/US2000/014705	5/31/2000	2000/072973	12/7/2000			INACTIVE
148428-001803-S	EUROPE	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	00937882.9	5/31/2000	1185371	3/13/2002	1185371	7/28/2004	Expired
148428-001804-S	JAPAN		SMALL-SCALE MILL AND METHOD THEREOF	2000-621075	5/31/2000	2003-500206	1/7/2003	4156807	7/18/2008	Expired
148428-001805-S	CANADA	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	2393195	5/31/2000	2393195	12/7/2000	2393195	2/20/2007	Expired
148428-001811-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	SMALL-SCALE HIGH ENERGY MILL AND METHOD THEREOF	10/037566	10/19/2001	2002-0145062	10/10/2002	6745962	6/8/2004	Expired
148428-001813-S	FRANCE	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	00937882.9	5/31/2000	1185371	3/13/2002	1185371	7/28/2004	Expired
148428-001814-S	GERMANY	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	00937882.9	5/31/2000	1185371	3/13/2002	600 12 520.3	7/28/2004	Expired
148428-001815-S	IRELAND	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	00937882.9	5/31/2000	1185371	3/13/2002	1185371	7/28/2004	Expired
148428-001816-S	ITALY	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	502008901664386	5/31/2000	1185371	3/13/2002	1185371	7/28/2004	Expired
148428-001817-S	UNITED KINGDOM	Elan Pharma International Limited	SMALL-SCALE MILL AND METHOD THEREOF	00937882.9	5/31/2000	1185371	3/13/2002	1185371	7/28/2004	Expired
148428-001821-S	UNITED STATES		METHOD OF USING A SMALL SCALE MILL	10/833045	4/28/2004	2004-0251332	12/16/2004	6991191	1/31/2006	Expired
148428-001900-S	UNITED STATES		APPARATUS FOR SANITARY WET MILLING	60/199923	4/26/2000					Expired
148428-001901-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	APPARATUS FOR SANITARY WET MILLING	09/842619	4/26/2001	2001-0053664	12/20/2001	6582285	6/24/2003	EXPIRED
148428-001902-S	WIPO	ELAN PHARMA INTERNATIONAL, LTD.	APPARATUS FOR SANITARY WET MILLING	PCT/US2001/013506	4/26/2001	2001/085344	11/15/2001			INACTIVE
148428-001904-S	JAPAN	Elan Pharma International Limited	APPARATUS FOR SANITARY WET MILLING	2001-581993	4/26/2001	2003-532525	11/5/2003	4343476	7/17/2009	EXPIRED
148428-001905-S	CANADA	Elan Pharma International Limited	APPARATUS FOR SANITARY WET MILLING	2406696	4/26/2001	2406696	11/15/2001	2406696	6/30/2009	EXPIRED
148428-001911-S	UNITED STATES	Elan Pharma International Ltd.	APPARATUS FOR SANITARY WET MILLING	10/258552	12/18/2002	2004-0026546	2/12/2004			Abandoned
148428-002000-S	UNITED STATES		SYSTEM AND METHOD FOR MILLING MATERIALS	60/295965	6/5/2001					Expired

148428-002001-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	SYSTEM AND METHOD OF MILLING MATERIALS	10/162333	6/4/2002	2002-0179758	12/5/2002	6742734	6/1/2004	EXPIRED
148428-002002-S	WIPO	Elan Pharma International Limited	SYSTEM AND METHOD OF MILLING MATERIALS	PCT/US2002/017323	5/31/2002	2002/098565	12/12/2002			NAT PHASE
148428-002003-S	EUROPE	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002004-S	JAPAN	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	2003-501597	5/31/2002	2004-535919	12/2/2004	4223390	11/28/2008	EXPIRED
148428-002005-S	CANADA	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	2449490	5/31/2002	2449490	12/12/2002	2449490	10/5/2010	EXPIRED
148428-002011-S	UNITED STATES		SYSTEM AND METHOD FOR MILLING MATERIALS	10/732801	12/11/2003	2004-0164194	8/26/2004	6976647	12/20/2005	EXPIRED
148428-002016-S	AUSTRIA	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	2002739588	7/23/2008	EXPIRED
148428-002017-S	BELGIUM	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002018-S	CYPRUS	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002019-S	DENMARK	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002021-S	UNITED STATES		COMPOSITIONS AND METHOD FOR MILLING MATERIALS	10/832374	4/27/2004	2004-0195413	10/7/2004			Abandoned
148428-002026-S	FINLAND	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002027-S	FRANCE	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002028-S	GERMANY	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	60227802.3	7/23/2008	EXPIRED
148428-002029-S	GREECE	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	20080402576	7/23/2008	EXPIRED
148428-002031-S	UNITED STATES		SYSTEM AND METHOD FOR MILLING MATERIALS	11/833645	8/3/2007	2008-0025807	1/31/2008	7575184	8/18/2009	EXPIRED
148428-002036-S	IRELAND	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002037-S	ITALY	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	502008901668211	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002038-S	LUXEMBOURG	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002039-S	MONACO	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002046-S	NETHERLANDS	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002047-S	PORTUGAL	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002048-S	SPAIN	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	2309177	7/23/2008	EXPIRED
148428-002049-S	SWEDEN	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002056-S	SWITZERLAND	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002057-S	TURKEY	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	2008 07967	7/23/2008	EXPIRED
148428-002058-S	UNITED KINGDOM	Elan Pharma International Limited	SYSTEM AND METHOD FOR MILLING MATERIALS	02739588.8	5/31/2002	1392441	3/3/2004	1392441	7/23/2008	EXPIRED
148428-002100-S	UNITED STATES		INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	60/873132	12/6/2006					Expired
148428-002101-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	11/951114	12/5/2007	2008-0139482	6/12/2008	8148398	4/3/2012	ISSUED
148428-002102-S	WIPO	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	PCT/US2007/024914	12/5/2007	2008/070121	6/12/2008			NAT PHASE
148428-002103-S	EUROPE	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	07862551.4	12/5/2007	2101772	9/23/2009	2101772	4/25/2012	ISSUED
148428-002104-S	JAPAN	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	2009-540280	12/5/2007	2010-511715	4/15/2010	5213137	3/8/2013	ISSUED
148428-002105-S	CANADA	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	2671904	12/5/2007	2671904	6/12/2008	2671904	7/3/2012	ISSUED
148428-002106-S	CHINA	Baudax Bio, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	200780050532.4	12/5/2007	101588803	11/25/2009	101588803	3/20/2013	ISSUED
148428-002107-S	AUSTRALIA	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	2007328210	12/5/2007	2007328210	6/12/2008	2007328210	3/7/2013	ISSUED
148428-002108-S	INDIA	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	2432/KOLNP/2009	12/5/2007	2432/KOLNP/2009	7/24/2009	287758	9/25/2017	ISSUED
148428-002116-S	GERMANY	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	07862551.4	12/5/2007	2101772	9/23/2009	602007022332.6	4/25/2012	ISSUED
148428-002117-S	FRANCE	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	07862551.4	12/5/2007	2101772	9/23/2009	2101772	4/25/2012	ISSUED
148428-002118-S	UNITED KINGDOM	Cornell Research Foundation, Inc.	INTERMEDIATE DURATION NEUROMUSCULAR BLOCKING AGENTS AND ANTAGONISTS THEREOF	07862551.4	12/5/2007	2101772	9/23/2009	2101772	4/25/2012	ISSUED
148428-002200-S	UNITED STATES		SYMMETRICAL AND ASYMMETRICAL ISOQUINOLINIUM MALEATES: NONDEPOLARIZING NEUROMUSCULAR BLOCKING DRUGS WHICH ARE IMMEDIATELY REVERSIBLE BY CYSTEINE AND GLUTATHIONE NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS	61/160915	3/17/2009					Expired
148428-002201-S	UNITED STATES	ATHYRIUM OPPORTUNITIES III ACQUISITION LP	REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE	13/257214	12/13/2011	2012-0095041	4/19/2012	8592451	11/26/2013	ISSUED
148428-002202-S	WIPO	Cornell University	REVERSIBLE NONDEPOLARIZING NEUROMUSCULAR BLOCKADE AGENTS AND METHODS FOR THEIR USE	PCT/US2010/000796	3/17/2010	2010/107488	9/23/2010			NAT PHASE
148428-002300-S	UNITED STATES		CYSTEINE FOR PHYSIOLOGICAL INJECTION	61/235191	8/19/2009					Expired
148428-002301-S	UNITED STATES	Cornell University	CYSTEINE FOR PHYSIOLOGICAL INJECTION	13/391154	5/7/2012	2012-0214873	8/23/2012	9220700	12/29/2015	ISSUED
148428-002302-S	WIPO	Cornell University	CYSTEINE FOR PHYSIOLOGICAL INJECTION	PCT/US2010/045907	8/18/2010	2011/022491	2/24/2011			NAT PHASE
148428-002308-S	CHINA	Cornell University	CYSTEINE FOR PHYSIOLOGICAL INJECTION	201080047362.6	8/18/2010	102573794	7/11/2012	102573794	3/15/2017	ISSUED
148428-002400-S	UNITED STATES		ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	61/666244	6/29/2012					Expired
148428-002401-S	UNITED STATES	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	14/411060	12/23/2014	2015-0191453	7/9/2015	9156826	10/13/2015	ISSUED

148428-002402-S	WIPO	SAVARESE, John, J. MCGILVRA, Jeff, D.	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	PCT/US2013/048771	6/28/2013	2014/005122	1/3/2014			NAT PHASE
148428-002403-S	EUROPE	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002404-S	JAPAN	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	2015-520604	6/28/2013	2015-522033	8/3/2015	6236077	11/2/2017	ISSUED
148428-002410-S	UNITED STATES		ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	61/703991	9/21/2012					Expired
148428-002414-S	JAPAN	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	2017-207722	6/28/2013	2018-048183	3/29/2018	6709205	5/26/2020	ISSUED
148428-002415-S	SPAIN	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2625329	2/15/2017	ISSUED
148428-002416-S	BELGIUM	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002417-S	SWITZERLAND	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002418-S	GERMANY	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	602013017541.1	2/15/2017	ISSUED
148428-002419-S	FRANCE	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002420-S	UNITED STATES		ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	61/817706	4/30/2013					Expired
148428-002424-S	JAPAN	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	2020-013449	6/28/2013	2020-063305	4/23/2020	7028474	2/21/2022	ISSUED
148428-002425-S	UNITED KINGDOM	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002426-S	IRELAND	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	13810090.4	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002427-S	ITALY	Cornell University	ASYMMETRICAL NEUROMUSCULAR BLOCKING AGENTS OF ULTRA-SHORT, SHORT, OR INTERMEDIATE DURATION	502017000045667	6/28/2013	2867219	5/6/2015	2867219	2/15/2017	ISSUED
148428-002500-S	UNITED STATES		REVERSAL OF CYSTEINE-INACTIVATED NEUROMUSCULAR BLOCKING DRUGS WITH COMBINATIONS OF REVERSAL AGENTS	61/841211	6/28/2013					Expired
148428-002502-S	WIPO	Cornell University	REVERSAL OF CYSTEINE-INACTIVATED NEUROMUSCULAR BLOCKING DRUGS WITH COMBINATIONS OF REVERSAL AGENTS	PCT/US2014/044422	6/26/2014	2014/210369	12/31/2014			Expired
148428-002600-S	UNITED STATES		METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	63/093527	10/19/2020					Abandoned
148428-002601-S	UNITED STATES	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	18/249,376	4/17/2023					PENDING
148428-002602-S	WIPO	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	PCT/US2021/055289	10/15/2021		4/21/2022			NAT PHASE
148428-002603-S	EUROPE	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	21881227.9	10/15/2021	4228760	8/23/2023			PUBLISHED
148428-002604-S	JAPAN	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	2023-522999	10/15/2021					PENDING
148428-002605-S	CANADA	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	3198628	10/15/2021					PENDING
148428-002607-S	AUSTRALIA	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	2021359825	10/15/2021					PENDING
148428-002608-S	CHINA	Cornell University	METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	202180085244.2	10/15/2021					PENDING
148428-002610-S	UNITED STATES		METHODS FOR CONTROLLING AND PREDICTING RECOVERY AFTER NMBA ADMINISTRATION	63/093179	10/17/2020					Expired
148428-002700	UNITED STATES		METHODS FOR INDUCING NEUROMUSCULAR BLOCKADE (NMB) WHILE MAINTAINING ACCEPTABLE INTUBATION CONDITIONS	63/501,606	5/11/2023					PENDING
148428-002800-S	UNITED STATES		METHODS OF PRODUCING T-CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS	61/576,837	12/16/2011					EXPIRED
148428-002801-S	UNITED STATES	THE USA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES	METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS	13/716,900	12/17/2012	2013-0157363	6/20/2013	9,481,866	11/1/2016	ISSUED
148428-002811-S	UNITED STATES	THE USA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES	METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS	15/284,840	10/4/2016	2017-0022478	1/26/2017	11,060,059	7/13/2021	ISSUED
148428-002821-S	UNITED STATES	THE USA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES	METHODS OF PRODUCING T CELL POPULATIONS ENRICHED FOR STABLE REGULATORY T-CELLS	17/371,589	7/9/2021	2022-0002672	1/6/2022			PUBLISHED
148428-002900	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	61/821,857	5/10/2013					EXPIRED
148428-002901	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	14/889,962	11/9/2015	2016-0194605	7/7/2016	10,093,901	10/9/2018	ISSUED
148428-002902	WIPO	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	PCT/US2014/037524	5/9/2014	2014/183056	11/13/2014			NAT PHASE
148428-002903	EUROPE	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	14794253.6	5/9/2014	3001836	4/6/2016	3001836	8/7/2019	ISSUED
148428-002911	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	16/123,499	9/6/2018	2019-0203174	7/4/2019	10,968,430	4/6/2021	ISSUED

148428-002913	GERMANY	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	14794253.6	5/9/2014	3001836	4/6/2016	602014051388.3	8/7/2019	ISSUED
148428-002914	FRANCE	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	14794253.6	5/9/2014	3001836	4/6/2016	3001836	8/7/2019	ISSUED
148428-002915	UNITED KINGDOM	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE	14794253.6	5/9/2014	3001836	4/6/2016	3001836	8/7/2019	ISSUED
148428-003000	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	CYTOTOXIC T CELLS AND BISPECIFIC ANTIBODIES FOR INDUCING IMMUNE TOLERANCE	62/263,108	12/4/2015					EXPIRED
148428-003001	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE	15/780,584	5/31/2018	2018-0369350	12/27/2018	11,090,373	8/17/2021	ISSUED
148428-003002	WIPO	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE	PCT/US2016/055656	10/6/2016	2017/095525	6/8/2017			NAT PHASE
148428-003003	EUROPE	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE	16871218.0	10/6/2016	3384013	10/10/2018			PUBLISHED
148428-003010	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC REGULATORY T CELLS FOR INDUCING IMMUNE TOLERANCE	62/359,886	7/8/2016					EXPIRED
148428-003011	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNE TOLERANCE	17/388,606	7/29/2021	2022-0054608	2/24/2022			PUBLISHED
148428-003020	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	ANTIGEN-SPECIFIC REGULATORY T CELLS FOR INDUCING IMMUNE TOLERANCE	62/393,245	9/12/2016					EXPIRED
148428-003100-S	UNITED STATES	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED	FVIII CHIMERIC ANTIGEN RECEPTOR TREGS FOR TOLERANCE INDUCTION IN HEMOPHILIA A	62/629,139	2/12/2018					EXPIRED
148428-003101-S	UNITED STATES	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED	FVIII CHIMERIC ANTIGEN RECEPTOR TREGS FOR TOLERANCE INDUCTION IN HEMOPHILIA A	16/969,353	8/12/2020	2021-0023170	1/28/2021			PUBLISHED
148428-003102-S	WIPO	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED	FVIII CHIMERIC ANTIGEN RECEPTOR TREGS FOR TOLERANCE INDUCTION IN HEMOPHILIA A	PCT/US2019/017630	2/12/2019	2019/157496	8/15/2019			NAT PHASE
148428-003200	UNITED STATES		INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	63/033,080	6/1/2020					EXPIRED
148428-003201	UNITED STATES	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	17/335,808	6/1/2021	2021-0371821	12/2/2021			PUBLISHED
148428-003202	WIPO	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	PCT/US2021/035226	6/1/2021	2021/247555	12/9/2021			NAT PHASE
148428-003203	EUROPE	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	21817717.8	6/1/2021	4157997	4/5/2023			PUBLISHED
148428-003204	JAPAN	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	2022-573461	6/1/2021	2023-527459	6/28/2023			PUBLISHED
148428-003205	CANADA	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	3179826	6/1/2021	3179826	12/9/2021			PUBLISHED
148428-003207	AUSTRALIA	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	2021283179	6/1/2021	2021283179	12/9/2021			PUBLISHED
148428-003208	CHINA	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	202180039213.3	6/1/2021	115768870	3/7/2023			PUBLISHED
148428-003209	SOUTH KOREA	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	10-2022-7046303	6/1/2021	10-2023-0019157	2/7/2023			PUBLISHED
148428-003258	HONG KONG	THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.	INDUCED REGULATORY T CELLS, METHODS OF PRODUCTION, AND USES THEREOF	62023078806.4	6/1/2021	40090014A	10/27/2023			PUBLISHED
148428-003300	UNITED STATES	TERAIMMUNE, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	63/170,214	4/2/2021					EXPIRED
148428-003301	UNITED STATES	TERAIMMUNE, LLC	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	17/709,979	3/31/2022	2022-0325243	10/13/2022	11,597,912	3/7/2023	ISSUED
148428-003302	WIPO	TERAIMMUNE, LLC	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	PCT/US2022/022823	3/31/2022	2022/212705	10/6/2022			NAT PHASE
148428-003303	EUROPE	TERAIMMUNE, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	22782213.7	3/31/2022					PENDING
148428-003304	JAPAN	TERAIMMUNE, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	2023-561149	3/31/2022					PENDING

148428-003305	CANADA	TERAimmune, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	3,214,000	3/31/2022					PENDING
148428-003307	AUSTRALIA	TERAimmune, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	2022249354	3/31/2022					PENDING
148428-003308	CHINA	TERAimmune, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	202280039576.1	3/31/2022					PENDING
148428-003309	SOUTH KOREA	TERAimmune, INC.	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	10-2023-7037798	3/31/2022					PENDING
148428-003311	UNITED STATES	TERAimmune, LLC	METHOD OF PRODUCING REGULATORY T CELLS BY CULTURING REGULATORY T CELLS OBTAINED FROM UMBILICAL CORD BLOOD	18/553,233	9/29/2023					PENDING
148428-003402-S	WIPO	SCM LIFESCIENCE CO., LTD. TERAimmune, INC.	COMBINED ADMINISTRATION COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS, COMPRISING FUNCTION-ENHANCED STEM CELLS AND REGULATORY T CELLS	PCT/KR2022/007696	5/30/2022	2022/255759	12/8/2022			PUBLISHED
148428-003409-S	SOUTH KOREA	SCM LIFESCIENCE CO., LTD. TERAimmune, INC.	COMBINED ADMINISTRATION COMPOSITION FOR PREVENTING OR TREATING ATOPIC DERMATITIS, COMPRISING FUNCTION-ENHANCED STEM CELLS AND REGULATORY T CELLS	10-2021-0070810	6/1/2021	10-2022-0162394	12/8/2022			PUBLISHED
148428-003509-S	SOUTH KOREA	THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NAT'L UNIVERSITY	COMPOSITION FOR PREVENTING, IMPROVING, OR TREATING ATOPIC DERMATITIS CONTAINING PROTEASOME INHIBITOR AS EFFECTIVE COMPONENT	10-2017-0105254	8/21/2017	10-2017-0105254	3/4/2019	101953671	3/4/2019	ISSUED

Fill in this information to identify the case:

Debtor name **Baudax Bio, Inc.**

United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**

Case number (if known) **24-10583**

☐ Check if this is an amended filing

Official Form 206D

Schedule D: Creditors Who Have Claims Secured by Property

12/15

Be as complete and accurate as possible.

1. Do any creditors have claims secured by debtor's property?

- ☐ No. Check this box and submit page 1 of this form to the court with debtor's other schedules. Debtor has nothing else to report on this form.
- ☒ Yes. Fill in all of the information below.

Part 1: List Creditors Who Have Secured Claims

2. List in alphabetical order all creditors who have secured claims. If a creditor has more than one secured claim, list the creditor separately for each claim.

		Column A Amount of claim Do not deduct the value of collateral.	Column B Value of collateral that supports this claim
2.1	MAM Eagle Lender, LLC Creditor's Name One Bryant Park, 38th Floor New York, NY 10036 Creditor's mailing address Creditor's email address, if known Date debt was incurred 5/29/20 Last 4 digits of account number Do multiple creditors have an interest in the same property? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Specify each creditor, including this creditor and its relative priority.	Describe debtor's property that is subject to a lien All property of the Debtor Describe the lien UCC - blanket security interest Is the creditor an insider or related party? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes Is anyone else liable on this claim? <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes. Fill out <i>Schedule H: Codebtors</i> (Official Form 206H) As of the petition filing date, the claim is: Check all that apply <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$3,605,555.56 Unknown

3. Total of the dollar amounts from Part 1, Column A, including the amounts from the Additional Page, if any.

\$3,605,555.56

Part 2: List Others to Be Notified for a Debt Already Listed in Part 1

List in alphabetical order any others who must be notified for a debt already listed in Part 1. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for secured creditors.

If no others need to be notified for the debts listed in Part 1, do not fill out or submit this page. If additional pages are needed, copy this page.

Name and address	On which line in Part 1 did you enter the related creditor?	Last 4 digits of account number for this entity
Wilmington Trust, National Association As Agent for MAM Eagle Lender, LLC 1100 N. Market Street Wilmington, DE 19890	Line 2.1	

Fill in this information to identify the case:

Debtor name **Baudax Bio, Inc.**

United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**

Case number (if known) **24-10583**

☐ Check if this is an amended filing

Official Form 206E/F

Schedule E/F: Creditors Who Have Unsecured Claims

12/15

Be as complete and accurate as possible. Use Part 1 for creditors with PRIORITY unsecured claims and Part 2 for creditors with NONPRIORITY unsecured claims. List the other party to any executory contracts or unexpired leases that could result in a claim. Also list executory contracts on *Schedule A/B: Assets - Real and Personal Property* (Official Form 206A/B) and on *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G). Number the entries in Parts 1 and 2 in the boxes on the left. If more space is needed for Part 1 or Part 2, fill out and attach the Additional Page of that Part included in this form.

Part 1: List All Creditors with PRIORITY Unsecured Claims

1. Do any creditors have priority unsecured claims? (See 11 U.S.C. § 507).

☐ No. Go to Part 2.

☒ Yes. Go to line 2.

2. List in alphabetical order all creditors who have unsecured claims that are entitled to priority in whole or in part. If the debtor has more than 3 creditors with priority unsecured claims, fill out and attach the Additional Page of Part 1.

		Total claim	Priority amount
2.1	<p>Priority creditor's name and mailing address</p> <p>Bong-Hyun Kim 10 Hackett Ct. Poolesville, MD 20837</p> <p>Date or dates debt was incurred Sept 2023 - Nov 2023</p> <p>Last 4 digits of account number</p> <p>Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: Wages</p> <p>Is the claim subject to offset?</p> <p><input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	<p>\$135,124.00</p> <p>\$15,150.00</p>
2.2	<p>Priority creditor's name and mailing address</p> <p>Charles A. Freyer 360 Pine Run Drive Osprey, FL 34229</p> <p>Date or dates debt was incurred Aug 2023 - Dec 2023</p> <p>Last 4 digits of account number</p> <p>Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)</p>	<p>As of the petition filing date, the claim is: <i>Check all that apply.</i></p> <p><input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed</p> <p>Basis for the claim: Wages</p> <p>Is the claim subject to offset?</p> <p><input checked="" type="checkbox"/> No <input type="checkbox"/> Yes</p>	<p>\$52,257.62</p> <p>\$2,257.62</p>

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

2.3	Priority creditor's name and mailing address Christopher T. Sharr 1581 Gulf Blvd. Clearwater Beach, FL 33767	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$51,936.57	\$15,150.00
Date or dates debt was incurred Aug 2023 - Nov 2023		Basis for the claim: Wages		
Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)		Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.4	Priority creditor's name and mailing address Comptroller of Maryland Compliance Division Bankruptcy Division 301 W. Preston Street, Room 409 Baltimore, MD 21201	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
Date or dates debt was incurred		Basis for the claim: notice purposes only		
Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)		Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.5	Priority creditor's name and mailing address Diane P. Myers 1232 Darby Hill Road Havertown, PA 19083	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$68,371.19	\$15,150.00
Date or dates debt was incurred Aug 2023 - Nov 2023		Basis for the claim: Wages		
Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)		Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.6	Priority creditor's name and mailing address Geraldine A. Henwood 1554 Paoli Pike No. 308 West Chester, PA 19380	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$249,423.08	\$15,150.00
Date or dates debt was incurred Aug 2023 - Dec 2023		Basis for the claim: Wages		
Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)		Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583	
--------	---------------------------------	------------------------	-----------------	--

2.7	Priority creditor's name and mailing address Internal Revenue Insolvency Unit 600 Arch Street Philadelphia, PA 19106	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
	Date or dates debt was incurred	Basis for the claim: notice purposes only		
	Last 4 digits of account number	Is the claim subject to offset?		
	Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.8	Priority creditor's name and mailing address Irene Kim 12582 Foreman Blvd. Clarksburg, MD 20871	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$35,877.08	\$0.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number	Is the claim subject to offset?		
	Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.9	Priority creditor's name and mailing address Jae Hyun Lim 9908 Bald Cypress Dr. Rockville, MD 20850	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$120,698.05	\$15,150.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number	Is the claim subject to offset?		
	Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.10	Priority creditor's name and mailing address Janice M. Trulli 230 East Benedict Avenue Havertown, PA 19083	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$40,277.12	\$15,150.00
	Date or dates debt was incurred Aug 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number	Is the claim subject to offset?		
	Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

2.11	Priority creditor's name and mailing address Jeong Heon Yoon 16 Chantilly Ct. Rockville, MD 20850	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$176,196.86	\$15,150.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.12	Priority creditor's name and mailing address Jihoon Park 18919 Festival Dr. Boys, MD 20841	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$169,760.86	\$15,150.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.13	Priority creditor's name and mailing address Jillian Dilmore 5 Willow Drive Malvern, PA 19355	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$30,352.00	\$0.00
	Date or dates debt was incurred Aug 2023 - Oct 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.14	Priority creditor's name and mailing address Maryland Department of Labor 1100 N. Eutaw Street Room 401 522 Baltimore, MD 21201	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
	Date or dates debt was incurred	Basis for the claim: notice purposes only		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

2.15	Priority creditor's name and mailing address Natalie K. McDevitt 4 Crescent Hill Drive Havertown, PA 19083	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$23,500.00	\$15,150.00
	Date or dates debt was incurred Aug 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.16	Priority creditor's name and mailing address Nicole R. Knapp-Kerper 559 Vanderslice Street Phoenixville, PA 19460	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$34,079.44	\$15,150.00
	Date or dates debt was incurred Aug 2023 - Dec 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.17	Priority creditor's name and mailing address PA Department of Labor and Industry 651 Boas Street Harrisburg, PA 17120	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
	Date or dates debt was incurred	Basis for the claim: notice purposes only		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.18	Priority creditor's name and mailing address Padma Priya Sekar 6000 California Circ. Apt. 111 Rockville, MD 20852	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$115,038.95	\$15,150.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

2.19	Priority creditor's name and mailing address Pennsylvania Dept. of Revenue Bankruptcy Division Dept. 280946 Harrisburg, PA 17128	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
	Date or dates debt was incurred	Basis for the claim: notice purposes only		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.20	Priority creditor's name and mailing address Securities & Exchange Commission Office of General Counsel Attn: Julia Lewis 100 F Street NE / Stop 9320/SP Washington, DC 20549	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$0.00	\$0.00
	Date or dates debt was incurred	Basis for the claim: notice purposes only		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (8)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.21	Priority creditor's name and mailing address Si Hyung Jang 3979 Ducks Foot Lane Ellicott City, MD 21042	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$99,398.75	\$15,150.00
	Date or dates debt was incurred Sept 2023 - Nov 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

2.22	Priority creditor's name and mailing address Syung-Yong Choi 3018 Kimberly Drive Norristown, PA 19401	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$88,500.88	\$15,150.00
	Date or dates debt was incurred Aug 2023 - Dec 2023	Basis for the claim: Wages		
	Last 4 digits of account number Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes		

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

2.23	Priority creditor's name and mailing address Yong Chan Kim 16 Chantilly Ct. Rockville, MD 20850	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed	\$139,779.66	\$15,150.00
------	---	--	---------------------	--------------------

Date or dates debt was incurred Sept 2023 - Dec 2023	Basis for the claim: Wages
--	--------------------------------------

Last 4 digits of account number	Is the claim subject to offset?
Specify Code subsection of PRIORITY unsecured claim: 11 U.S.C. § 507(a) (4)	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes

Part 2: List All Creditors with NONPRIORITY Unsecured Claims

3. List in alphabetical order all of the creditors with nonpriority unsecured claims. If the debtor has more than 6 creditors with nonpriority unsecured claims, fill out and attach the Additional Page of Part 2.

			Amount of claim
3.1	Nonpriority creditor's name and mailing address A&L Goodbody International Financial Services North Wall Quay Dublin 1 IRELAND Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Ireland legal/professional services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$10,226.83
3.2	Nonpriority creditor's name and mailing address ABC/Amega Collection Bureau for Digital Media Innovations, LLC 500 Seneca Street, Suite 503 Buffalo, NY 14204-1963 Date(s) debt was incurred ____ Last 4 digits of account number <u>2353</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Digital Media</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,270.00
3.3	Nonpriority creditor's name and mailing address Accenture LLP 161 N. Clark Street Chicago, IL 60601 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Regulatory specialized format for FDA and EU filings for drugs</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$17,413.00
3.4	Nonpriority creditor's name and mailing address Advarra, Inc. 4445 Lake Forest Drive Suite 300 Cincinnati, OH 45242 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Research Review Board service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$17,810.00
3.5	Nonpriority creditor's name and mailing address Agilent Technologies, Inc. 5301 Stevens Creek Blvd. Santa Clara, CA 95051 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Sample analysis for stability of compounds</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,119.60

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.6	Nonpriority creditor's name and mailing address Almac Sciences Ireland Ltd (fka Bioclin Research Laboratories) IDA Technology & Business Park Garrycastle, Athlor, Ireland, N37X061 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IRELAND - Analytical testing for commercial product</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$31,758.25
-----	--	--	--------------------

3.7	Nonpriority creditor's name and mailing address AlphaVektor, LLC 11113 Alison Parke Trail Austin, TX 78755 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Formulation and CMC consulting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$20,050.00
-----	---	---	--------------------

3.8	Nonpriority creditor's name and mailing address Alturas Analytics, Inc. 1324 Altuas Drive Moscow, ID 83843 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>MS/MS bioanalytical services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$32,228.73
-----	---	---	--------------------

3.9	Nonpriority creditor's name and mailing address American Express P.O. Box 6031 Carol Stream, IL 60197-6031 Date(s) debt was incurred _____ Last 4 digits of account number <u>1004</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Corporate Card</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,855.62
-----	--	---	-------------------

3.10	Nonpriority creditor's name and mailing address American Express PO Box 6031 Carol Stream, IL 60197-6031 Date(s) debt was incurred _____ Last 4 digits of account number <u>1009</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Corporate Card</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$25.00
------	--	---	----------------

3.11	Nonpriority creditor's name and mailing address American Society for Enhanced Recovery 2111 Chestnut Avenue Suite 145 Glenview, IL 60025 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Advisors for Neurmuscular Blockers</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$24,000.00
------	---	---	--------------------

3.12	Nonpriority creditor's name and mailing address American Society of Anesthesiologists 1061 American Lane Schaumburg, IL 60173-4973 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Advisors for anesthesia</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$77,500.00
------	---	--	--------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.13	Nonpriority creditor's name and mailing address American Society of Colon and Rectal Surgeons One Prakview Plaza Suite 800 Villa Park, IL 60181 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Advisors on bowel surgeries</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,600.00
3.14	Nonpriority creditor's name and mailing address Amy Thomas 1511 N. Bailey Road Downingtown, PA 19335 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - administrative support</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$36,925.94
3.15	Nonpriority creditor's name and mailing address Andrew Dreschler 114 Woodland Avenue Avon by the Sea, NJ 07717 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services as member of Board of Directors and head of audit committee</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$45,000.00
3.16	Nonpriority creditor's name and mailing address AON Consulting, Inc. PO Box 100137 Pasadena, CA 91189-0137 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - commercial transportation and risk reduction</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,280.00
3.17	Nonpriority creditor's name and mailing address Aon Risk Services Central, Inc. Aon Risk Services Companies, Inc. PO Box 7247-7376 Philadelphia, PA 19170-7376 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Insurance - D&O and general business insurance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$0.00
3.18	Nonpriority creditor's name and mailing address ARE-Maryland No. 52, LLC Attention: Corporate Secretary 26 North Euclid Avenue Pasadena, CA 91101 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Office lease located at 20400 Century Boulevard, Suite 125, Germantown, MD 20874</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$60,000.00
3.19	Nonpriority creditor's name and mailing address Argot Partners, LLC 767 Third Avenue 34th Floor New York, NY 10017 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - investor relations</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$80,744.45

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.20	Nonpriority creditor's name and mailing address Arnold M. Baskies, MD 57 Festival Drive Voorhees, NJ 08043 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Services as member of Board of Directors</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$30,000.00
------	---	---	--------------------

3.21	Nonpriority creditor's name and mailing address Baker Tilly US, LLP Box 78975 Milwaukee, WI 53278-8975 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Lessor for accounting system (Intact)</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,620.91
------	---	--	--------------------

3.22	Nonpriority creditor's name and mailing address Ballard Spahr 2000 South 8th Street Minneapolis, MN 55402-2274 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,920.00
------	---	---	-------------------

3.23	Nonpriority creditor's name and mailing address Baylor College of Medicine One Baylor Plaza CBMN 505 Houston, TX 77030 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralimmune consulting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,550.00
------	---	---	-------------------

3.24	Nonpriority creditor's name and mailing address BDO USA, LLP 770 Kenmoor SE Suite 300 Grand Rapids, MI 49546 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>SOX compliance testing for SEC, audit compliance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$19,414.00
------	---	---	--------------------

3.25	Nonpriority creditor's name and mailing address Becton Dickinson Beckton, Dickinson & Company PO Box 28983 New York, NY 10087-8983 Date(s) debt was incurred _____ Last 4 digits of account number 5699	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Lab equipment relocation services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,375.00
------	---	--	-------------------

3.26	Nonpriority creditor's name and mailing address BGR Government Affairs, LLC 601 Thirteenth Street NW Eleventh Floor South Washington, DC 20005 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - lobbying US Congress</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$72,132.94
------	---	--	--------------------

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.27	Nonpriority creditor's name and mailing address BIO Korea 1st Floor, Building C 700 Daewangpangyo-ro, Bundang-gu, Seongn-si, Gyeonggi-do Republic of Korea 13488 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Membership fee</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,400.00
------	---	--	-------------------

3.28	Nonpriority creditor's name and mailing address Biocair Inc. 30 Tower Office Park Woburn, MA 01801 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Cell therapy courier services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,740.88
------	---	---	-------------------

3.29	Nonpriority creditor's name and mailing address BioPharm Communications 290 Union Square Drive New Hope, PA 18938 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralmmune promotion agency services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$44,116.00
------	--	--	--------------------

3.30	Nonpriority creditor's name and mailing address Birch Partners Consulting, LLC 1633 Valley Greene Road Paoli, PA 19301 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - clinical operations</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$79,812.50
------	---	--	--------------------

3.31	Nonpriority creditor's name and mailing address Broadridge Corp. Issuer Solutions, Inc. PO Box 417106 Boston, MA 02241 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Stock transfer agent services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,611.24
------	---	---	--------------------

3.32	Nonpriority creditor's name and mailing address Broadridge Investor Comm. Solutions, Inc PO Box 416423 Boston, MA 02241-6423 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Stock transfer agent services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$149,210.72
------	---	---	---------------------

3.33	Nonpriority creditor's name and mailing address CCHMC 3333 Burnett Avenue Cincinnati, OH 45229-3039 Date(s) debt was incurred ____ Last 4 digits of account number <u>5247</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>GMP viral vector manufacturing</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$118,845.99
------	---	--	---------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.34	Nonpriority creditor's name and mailing address Certara USA, Inc. Box 32080 New York, NY 10087-2080 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Bioanalytical modeling</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$38,106.25
------	--	--	--------------------

3.35	Nonpriority creditor's name and mailing address Charles River Laboratories Incorporated 22022 Transcanadienne Senneville, QC H9X 3R3 CANADA Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Preclinical site - GLP studies BX 3000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$29,675.00
------	--	--	--------------------

3.36	Nonpriority creditor's name and mailing address Chase Credit Card PO Box 6294 Carol Stream, IL 60197-6294 Date(s) debt was incurred _____ Last 4 digits of account number <u>4354</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Credit card</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$33,515.88
------	--	---	--------------------

3.37	Nonpriority creditor's name and mailing address Christina Carnegie Consultancy, Ltd. Llanvihangel Court Llansoy, Usk Monmouthshire NP15 1DU Wales, UK Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>International consultant in anesthesia products</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$29,202.00
------	--	---	--------------------

3.38	Nonpriority creditor's name and mailing address Clinical Supplies Management Holdings, Inc. 300 Technology Drive Malvern, PA 19355 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Drug packaging for trials</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$35,900.87
------	---	---	--------------------

3.39	Nonpriority creditor's name and mailing address Cogent Communications, Inc. PO Box 791087 Baltimore, MD 21279-1087 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Internet service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$16,341.02
------	---	---	--------------------

3.40	Nonpriority creditor's name and mailing address Comstar Technologies 1155 Phoenixville Pike Suite 114-115 West Chester, PA 19380 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Utilities</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,276.33
------	---	---	--------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.41	Nonpriority creditor's name and mailing address Concur Technologies, Inc. 601 108th Avenue NE Suite 1000 Bellevue, WA 98004 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Expense management services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,309.34
<hr/>			
3.42	Nonpriority creditor's name and mailing address CoPilot Provider Support Services, Inc. 1981 Marcus Avenue Suite C130 Elmont, NY 11003 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Product reimbursement services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$17,500.00
<hr/>			
3.43	Nonpriority creditor's name and mailing address Copyright Clearance Center 29118 Network Place Chicago, IL 60673-1291 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Copyright registration fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,025.00
<hr/>			
3.44	Nonpriority creditor's name and mailing address Cornell University (Tech Licensing) 395 Pine Tree Road Suite 310 Ithaca, NY 14850 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Licensing and patent fees for BX 1000, 2000 and 3000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$124,419.39
<hr/>			
3.45	Nonpriority creditor's name and mailing address Curia Wisconsin, Inc. 870 Badger Circle Grafton, WI 53024 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>API manufacturing for Bx 1000, Bx 2000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$34,374.87
<hr/>			
3.46	Nonpriority creditor's name and mailing address Danforth Advisors LLC PO Box 335 Southborough, MA 01772 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Temporary senior professional services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$90,817.50
<hr/>			
3.47	Nonpriority creditor's name and mailing address DataWatch 4520 East West Highway Suite 200 Bethesda, MD 20814 Date(s) debt was incurred _____ Last 4 digits of account number <u>6766</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Installation advice and the door security system at 20400 Century Blvd.</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$23,975.00

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

3.48	Nonpriority creditor's name and mailing address De Lage Landen Financial Services, Inc. 1111 Old Eeagle School Road Suite 1 Wayne, PA 19087 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Utilities</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,673.33
------	--	---	-------------------

3.49	Nonpriority creditor's name and mailing address Definitive Healthcare, LLC Now: Joseph, Mann and Creed Collection Agency 550 Cochituate Road, Unit 4 Framingham, MA 01701 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Data analytics for hospital data</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$10,118.50
------	--	--	--------------------

3.50	Nonpriority creditor's name and mailing address Deloitte Tax LLP 4022 Sells Drive Hermitage, TN 37076 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Tax accounting; tax planning</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$60,000.00
------	--	--	--------------------

3.51	Nonpriority creditor's name and mailing address DLA Piper PO Box 780528 Philadelphia, PA 19178-0528 Date(s) debt was incurred ____ Last 4 digits of account number <u>8428</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$297,815.88
------	---	--	---------------------

3.52	Nonpriority creditor's name and mailing address DLA Piper LLP (US) 6225 Smith Avenue Baltimore, MD 21209 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IP legal services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$340,540.47
------	---	---	---------------------

3.53	Nonpriority creditor's name and mailing address Donnelley Financial, LLC PO Box 531832 Atlanta, GA 30353-1832 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Publishing quarterly, annual and shareholder meeting materials as well as 8k formatting and publishing</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$416,100.00
------	--	--	---------------------

3.54	Nonpriority creditor's name and mailing address Donohue Advisory Associates LLC 9801 Washington Blvd. Suite 340 Gaithersburg, MD 20878 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Nasdaq legal counsel regarding shareholder equity compliance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$7,000.00
------	---	--	-------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.55	Nonpriority creditor's name and mailing address DSG CDM, LLC 325 Technology Drive Malvern, PA 19355 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$60,415.00 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical trial electronic data management for BX 2000 and BX 1000 clinical trials</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.56	Nonpriority creditor's name and mailing address Dun Laoghaire Rathdown County Council County Hall - Marine Road Dun Laoghaire County Dublin Ireland Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$1,916.57 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Rent for office lease located at Block 2 Harbour Square, 5th Floor, Frofton Road, Dun Laughoire, County Dublin, Ireland</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.57	Nonpriority creditor's name and mailing address Dun Laoghaire-Rathdown County Council Rates Office County Hall Dun Laoghaire CO IRELAND Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$35,546.97 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input checked="" type="checkbox"/> Disputed Basis for the claim: <u>Rent accrual after lease termination</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.58	Nonpriority creditor's name and mailing address E*Trade Financial Corporate Services Attn: Accounts Receivable PO Box 3512 Arlington, VA 22203 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$10,725.00 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Equity security services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.59	Nonpriority creditor's name and mailing address Eisneramper LLP 733 Third Avenue New York, NY 10017 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$283,875.00 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Public company auditor Q3 2022 - Q2 2023</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.60	Nonpriority creditor's name and mailing address Emtech 2377 Crenshaw Blvd. Suite 270 Torrance, CA 90501 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$390.00 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Banking service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes
3.61	Nonpriority creditor's name and mailing address Equisolve, Inc. 3500 SW Corporate Parkway Suite 206 Palm City, FL 34990 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> \$2,195.00 <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Management of SEC compliance for company website</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
--------	---------------------------------	------------------------	-----------------

3.62	Nonpriority creditor's name and mailing address Equity Plan Solutions, LLC 1495 Virginia Avenue Redwood City, CA 94061 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - stock plan</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,825.00
------	---	--	--------------------

3.63	Nonpriority creditor's name and mailing address eResearch Technology, Inc. PO Box 536636 Pittsburgh, PA 15203-5908 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Research administration services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$48,919.03
------	---	---	--------------------

3.64	Nonpriority creditor's name and mailing address ERG Holding Company, LLC Dept. #5614 PO Box 790126 Saint Louis, MO 63179-0126 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical research services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$916,933.72
------	--	---	---------------------

3.65	Nonpriority creditor's name and mailing address Eurofins Advantar Laboratories, Inc. 5451 Oberlin Drive Suite 100 San Diego, CA 92121 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Formulation and preclinical manufacturer of BX 3000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$30,133.47
------	--	--	--------------------

3.66	Nonpriority creditor's name and mailing address Ewing Cole 810 Ligh Street Baltimore, MD 21230 Date(s) debt was incurred ____ Last 4 digits of account number <u>2921</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Architect/engineer for 20400 Century Blvd.</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,446.00
------	---	---	--------------------

3.67	Nonpriority creditor's name and mailing address eXpd8 BBS Limited Unit 3C Swords Business Swords CO IRELAND Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IT support for Ireland location</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$36.90
------	--	--	----------------

3.68	Nonpriority creditor's name and mailing address Eze Castle Integration, Inc. 100 High Street 16th Floor Boston, MA 02110 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Alpha vector/IT support</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$41,558.82
------	---	--	--------------------

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.69	Nonpriority creditor's name and mailing address Facility Logix, LLC 3901 National Drive Burtonsville, MD 20866 Date(s) debt was incurred ____ Last 4 digits of account number <u>6101</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Project management for 20400 Century Blvd.</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,557.16
------	--	--	-------------------

3.70	Nonpriority creditor's name and mailing address Firefly Solutions, LLC 16 Tall Timber Lane Basking Ridge, NJ 07920 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Provider of commercial compliance software</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,000.00
------	---	--	-------------------

3.71	Nonpriority creditor's name and mailing address Foley & Lardner, LLP 3000 K Street NW Suite 600 Washington, DC 20007 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IP legal counsel</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,395.87
------	---	--	-------------------

3.72	Nonpriority creditor's name and mailing address FX2 LLC 2052 Ashburton Way Mount Pleasant, SC 29466 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Leased sales persons</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$16,800.00
------	--	--	--------------------

3.73	Nonpriority creditor's name and mailing address Goodwin Procter LLP 100 Northern Avenue Boston, MA 02110 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Corporate counsel/SEC counsel</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,811,579.63
------	---	---	-----------------------

3.74	Nonpriority creditor's name and mailing address Greenleaf Health, Inc. 1055 Thomas Jefferson St. NW Suite 450 Washington, DC 20007 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant - FDA discussions</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$48,000.00
------	---	--	--------------------

3.75	Nonpriority creditor's name and mailing address Health Products Regulatory Authority Earlsfort Centre Earlsfort Terrace Dublin 2 IRELAND Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Irish Regulatory Authority</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,947.87
------	---	--	-------------------

Debtor	Baudax Bio, Inc. Name	Case number (if known)	24-10583
3.76	Nonpriority creditor's name and mailing address Henry M. Jackson Foundation 6720-A Rockledge Drive Suite 100 Bethesda, MD 20817 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Royalties</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$112,500.00</u>
3.77	Nonpriority creditor's name and mailing address HiTech Health Ltd 5-7 Main Street Blackrock CO Dublin Ireland Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IRELAND - CMC consulting and regulatory support</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$36,743.98</u>
3.78	Nonpriority creditor's name and mailing address Hogan Lovells US LLP PO Box 75890 Baltimore, MD 21275-5890 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Regulatory counsel for FDA discussions</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$29,407.05</u>
3.79	Nonpriority creditor's name and mailing address Horne LLP PO Box 2153 Birmingham, AL 35287-9331 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Terimmune auditors</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$75,000.00</u>
3.80	Nonpriority creditor's name and mailing address Integrated Commercialization Solutions, LLC 3101 Gaylord Parkway Frisco, TX 75034 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Logistics services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$46,240.65</u>
3.81	Nonpriority creditor's name and mailing address Integrichain, Inc. 8 Penn Cernter, 3rd Floor 1628 JFK Blvd. Philadelphia, PA 19103 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Product pricing/rebate compliance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$1,500.00</u>
3.82	Nonpriority creditor's name and mailing address Intrado Digital Media, LLC Office of General Counsel 11808 Miracle Hills Drive Omaha, NE 68154 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Quarterly and annual call services for shareholders</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	<u>\$9,000.00</u>

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.83	Nonpriority creditor's name and mailing address inWorks, LLC PO Box 342 Uwchland, PA 19480 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Workspace services for building repairs</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$276.39
------	---	--	-----------------

3.84	Nonpriority creditor's name and mailing address IQ EQ Corporate Services (IRE) Limited Suite 6, Rineanna House Shannon Free Zone CO IRELAND Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IRELAND - financial support services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,078.69
------	--	---	-------------------

3.85	Nonpriority creditor's name and mailing address IQVIA RDS, Inc. (FKA Quintiles, Inc.) 4820 Emperor Blvd. Durham, NC 27703 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical drug safety services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,581.16
------	--	--	--------------------

3.86	Nonpriority creditor's name and mailing address Jae Min Cho 13822 Harrier Way Clarksburg, MD 20871 Date(s) debt was incurred <u>Sept 2022</u> Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Promissory note</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,250.00
------	---	--	--------------------

3.87	Nonpriority creditor's name and mailing address JBR Clinical Research 650 East 4500 South Suite 100 Salt Lake City, UT 84107 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical trial site for BX 1000 and BX 2000 studies</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$397,868.42
------	---	--	---------------------

3.88	Nonpriority creditor's name and mailing address John Goll 4 Barnard Place Pompton Plains, NJ 07444 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Post-acquisition accounting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,925.89
------	---	--	-------------------

3.89	Nonpriority creditor's name and mailing address John Savarese 71 Glen Lane Southbury, CT 06488 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Consultant anesthesiologist</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,000.00
------	---	--	--------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.90	Nonpriority creditor's name and mailing address Junho Cho 244 Congressional Lane Rockville, MD 20852 Date(s) debt was incurred <u>Sept 2022</u> Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Promissory note</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$10,120.00
3.91	Nonpriority creditor's name and mailing address Karam Accounting 11 Deer Park Drive, Suite 102A Monmouth Junction, NJ 08852 Date(s) debt was incurred _____ Last 4 digits of account number <u>9203</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Payroll processing; monthly accounting review; quarterly compilation report; tax return</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$25,262.42
3.92	Nonpriority creditor's name and mailing address Karebay 11 Deer Paqrk Drive, Suite 102A Monmouth Junction, NJ 08852 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Manufacturing GMP material (BHKps25, oligonucleotide)</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$80,000.00
3.93	Nonpriority creditor's name and mailing address Key Clinical Trial Services 1200 South 2000 East Salt Lake City, UT 84108 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>CRA monitoring</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,145.61
3.94	Nonpriority creditor's name and mailing address Kingsdale Shareholder Services US Inc. 745 Fifth Avenue 5th Floor New York, NY 10151 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Proxy solicitation services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$18,180.66
3.95	Nonpriority creditor's name and mailing address KPMG Dept. 0522 PO Box 120522 Dallas, TX 75312-0522 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Public accounting auditor</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$120,000.00
3.96	Nonpriority creditor's name and mailing address KPMG - Dublin 1 Stokes Place St. Stephen's Green D02 DE03 IRELAND Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IRELAND - accounting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$31,142.18

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.97	Nonpriority creditor's name and mailing address Labcorp Early Development Laboratories, Inc. PO Box 2464 Burlington, NC 27216 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Preclinical lab services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$324,051.87
------	--	---	---------------------

3.98	Nonpriority creditor's name and mailing address Layer 8 Security, LLC 5 Great Valley Parkway Suite 130 Malvern, PA 19355 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IT SEC compliance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,900.00
------	---	--	-------------------

3.99	Nonpriority creditor's name and mailing address LifeSci Advisors, LLC 250 West 55th Street 34th Floor New York, NY 10019 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IR/PR services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$188,714.59
------	---	---	---------------------

3.100	Nonpriority creditor's name and mailing address Lifeworks US, Inc. PO Box 775226 Chicago, IL 60677-5226 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Employee benefits</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,086.80
-------	--	--	-------------------

3.101	Nonpriority creditor's name and mailing address Loonhills R&D Inc. 5320 13e Avenue Montreal, WC H1X 2X8 CANADA Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>R&D tox labs</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,178.50
-------	---	---	--------------------

3.102	Nonpriority creditor's name and mailing address Lyophilizatin Technology, Inc. 30 Indian Drive Warminster, PA 18974 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>BX 3000 clinical trial drug lyophilization</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$106,516.67
-------	--	---	---------------------

3.103	Nonpriority creditor's name and mailing address Masako Consulting, LLC 2020 Grand River Anx Suite 100 Brighton, MI 48114 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Monitoring services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$8,331.00
-------	---	--	-------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.104	Nonpriority creditor's name and mailing address McKesson Medical - Surgical Inc. 9954 Maryland Drive Suite 4000 Henrico, VA 23233 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Specialty distributor for ASCs</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,593.30
-------	--	---	-------------------

3.105	Nonpriority creditor's name and mailing address MedDoc Acquisition 13826 Grey Colt Drive Gaithersburg, MD 20878-3867 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Data list services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$100.00
-------	---	---	-----------------

3.106	Nonpriority creditor's name and mailing address Mediant Communications, Inc. PO Box 29976 New York, NY 10087-9976 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Investor/trader and proxy vote number services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,774.23
-------	--	---	-------------------

3.107	Nonpriority creditor's name and mailing address Mele Associates 11 Taft Court Suite 101 Rockville, MD 20850 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Installation of the wired/wireless network at 20400 Century Blvd.</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,429.97
-------	--	--	-------------------

3.108	Nonpriority creditor's name and mailing address Nasdaq Stock Market, LLC PO Box 780700 Philadelphia, PA 19178-0700 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Stock market trading platform fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$18,937.84
-------	---	---	--------------------

3.109	Nonpriority creditor's name and mailing address Navex Global, Inc. 5500 Meadows Road Suite 500 Lake Oswego, OR 97035 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Employee benefits</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,086.70
-------	---	--	-------------------

3.110	Nonpriority creditor's name and mailing address NetMedia Solutions LLC 100 W. Main Street Suite 206 Lansdale, PA 19446 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IT services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$22,314.16
-------	---	--	--------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.111	Nonpriority creditor's name and mailing address NIH Government Lockbox 3180 River Trail S. Earth City, MO 63045 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Royalties</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$59,500.00
3.112	Nonpriority creditor's name and mailing address Noble Capital Markets, Inc. 150 East Palmetto Park Road Suite 110 Boca Raton, FL 33432 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Fairness opinion</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$120,000.00
3.113	Nonpriority creditor's name and mailing address Patheon UK Limited Kingfisher Drive Covingham Swindon Wiltshire IRELAND Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Finished product fill</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$59,520.09
3.114	Nonpriority creditor's name and mailing address Pay Governance, LLC Two Logan Square 100 N. 18th Street Suite 821 Philadelphia, PA 19103 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Board consultant for compensation</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,142.50
3.115	Nonpriority creditor's name and mailing address PECO Payment Processing PO Box 37629 Philadelphia, PA 19101-0629 Date(s) debt was incurred _____ Last 4 digits of account number <u>9043</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Utilities</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$351.28
3.116	Nonpriority creditor's name and mailing address PECO PO Box 37629 Philadelphia, PA 19101-0629 Date(s) debt was incurred _____ Last 4 digits of account number <u>0030</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Utilities</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,045.08
3.117	Nonpriority creditor's name and mailing address Pedley Law, PLLC 4365 S. Alton Way Englewood, CO 80111 Date(s) debt was incurred _____ Last 4 digits of account number <u>6759</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal counsel for M&A</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,225.00

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.118	Nonpriority creditor's name and mailing address Pinecone41, Inc. 3031 Tisch Way 110 PO San Jose, CA 95128 Date(s) debt was incurred ____ Last 4 digits of account number 2117	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>R&D tax credit submission</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$26,000.00
<hr/>			
3.119	Nonpriority creditor's name and mailing address Pitney Bowes 27 Waterview Drive Shelton, CT 06484 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Lease payment</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$193.20
<hr/>			
3.120	Nonpriority creditor's name and mailing address PNC Bank The Tower at PNC Plaza 300 Fifth Avenue Pittsburgh, PA 15222 Date(s) debt was incurred ____ Last 4 digits of account number 5792	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Credit Card</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,386.64
<hr/>			
3.121	Nonpriority creditor's name and mailing address PNC Bank The Tower at PNC Plaza 300 Fifth Avenue Pittsburgh, PA 15222 Date(s) debt was incurred ____ Last 4 digits of account number 3328	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Credit Card</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$13,970.72
<hr/>			
3.122	Nonpriority creditor's name and mailing address PNC Bank The Tower at PNC Plaza 300 Fifth Avenue Pittsburgh, PA 15222 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Letter of credit (Teralmmune commercial lease)</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$90,000.00
<hr/>			
3.123	Nonpriority creditor's name and mailing address PNC Bank The Tower at PNC Plaza 300 Fifth Avenue Pittsburgh, PA 15222 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input checked="" type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Letter of credit (Baudax Bio commercial lease)</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$100,000.00
<hr/>			
3.124	Nonpriority creditor's name and mailing address Pope & Associates, LLC 5171 Mohawk Lane Ogden, UT 84403 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Business consulting services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$15,806.20

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.125	Nonpriority creditor's name and mailing address Potomac Law Group 1717 Pennsylvania Avenue, NW Suite 1025 Washington, DC 20006 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IP management services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,393.70
-------	---	---	-------------------

3.126	Nonpriority creditor's name and mailing address PPD Development, LP 929 North Front Street Wilmington, NC 28401 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>E&L testing of commercial product</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$30,150.00
-------	--	--	--------------------

3.127	Nonpriority creditor's name and mailing address PRI Healthcare Solutions, LP 461 From Road Suite 190 Paramus, NJ 07652 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical services for NMB studies</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$32,796.68
-------	---	--	--------------------

3.128	Nonpriority creditor's name and mailing address Proshred Security 25 Industrial Blvd. Paoli, PA 19301 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Confidential waste shredding</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$766.15
-------	--	---	-----------------

3.129	Nonpriority creditor's name and mailing address Quality Chemical Laboratories, LLC 3400 Enterprise Drive Wilmington, NC 28405 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Analytical testing for BX 3000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$111,195.00
-------	--	---	---------------------

3.130	Nonpriority creditor's name and mailing address Reed Smith 599 Lexington Avenue New York New York, NY 10022-7650 Date(s) debt was incurred _____ Last 4 digits of account number <u>2986</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal advice on the potential joint venture deal</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,312.70
-------	--	---	-------------------

3.131	Nonpriority creditor's name and mailing address Rubin and Rudman 53 State Street Boston, MA 02109 Date(s) debt was incurred _____ Last 4 digits of account number <u>1569</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal counsel for investment and HR documents</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,714.50
-------	---	--	--------------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.132	Nonpriority creditor's name and mailing address Sagamore Sales and Marketing, Inc. 569 Main Street Suite 201 Warren, RI 02885 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Marketing/sales services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,500.00
<hr/>			
3.133	Nonpriority creditor's name and mailing address Say Technologies, LLC 85 Willow Road Menlo Park, CA 94025 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Shareholder services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,985.78
<hr/>			
3.134	Nonpriority creditor's name and mailing address SCP Vitalife Partners II, LP 5 Great Valley Parkway Suite 210 Malvern, PA 19355 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Board fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$61,666.67
<hr/>			
3.135	Nonpriority creditor's name and mailing address Sejong LLP 65 Challenger Road Suite 250 Ridgefield Park, NJ 07660 Date(s) debt was incurred ____ Last 4 digits of account number <u>9991</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralimmune independent accountant</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$17,500.00
<hr/>			
3.136	Nonpriority creditor's name and mailing address Selection.com 155 Tri-County Prkwy Suite 150 Cincinnati, OH 45246 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Temp labor/recruiting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$509.20
<hr/>			
3.137	Nonpriority creditor's name and mailing address Sesnzime, Inc. 5072 Annuciation Circle Suite 220 Immokalee, FL 34142 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralimmune patient identification</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,140.42
<hr/>			
3.138	Nonpriority creditor's name and mailing address Sharp Packaging Solutions 23 Carland Road Conshohocken, PA 19428 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Commerical packaging</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$22,180.17

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.139	Nonpriority creditor's name and mailing address Sheppard Mullin 333 South Hope STreet, 43rd Floor 5493, CA 90071-1422 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Trademark filing and management</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$23,714.86
-------	--	--	--------------------

3.140	Nonpriority creditor's name and mailing address Shoals Medical Trials, Inc. 1300 South Montgomery Avenue Sheffield, AL 35660 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical NMB trials</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$6,566.74
-------	---	--	-------------------

3.141	Nonpriority creditor's name and mailing address Stewart McCallum 1401 Kyneton Road Villanova, PA 19085 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical and pharmaceutical consulting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$150,000.00
-------	---	---	---------------------

3.142	Nonpriority creditor's name and mailing address Stout Risius Ross, LLC 150 W. Second Street Suite 400 Royal Oak, MI 48067 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Accounting specialist</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$239,037.50
-------	--	--	---------------------

3.143	Nonpriority creditor's name and mailing address Sughrue 2000 Pennsylvania Avenue, NW Suite 9000 Washington, DC 20006 Date(s) debt was incurred _____ Last 4 digits of account number <u>5035</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>IP management</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$12,571.57
-------	--	--	--------------------

3.144	Nonpriority creditor's name and mailing address Synchrony Healthcare Communications, Inc 22 N. Church Street West Chester, PA 19380 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Service provider for reimbursement Hub</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$23,193.75
-------	--	---	--------------------

3.145	Nonpriority creditor's name and mailing address SZH Consulting 2737 Lantern Lane Norristown, PA 19403 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Terimmune HR consulting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$123,250.00
-------	--	--	---------------------

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.146	Nonpriority creditor's name and mailing address The FKM Group FKM Engineering Limited 3013 Lake Drive Dublin 24 IRELAND Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Design/contractor services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$468.06
-------	--	--	-----------------

3.147	Nonpriority creditor's name and mailing address The Griesser Group, LLC 107 N. Drexel Avenue Havertown, PA 19083 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Clinical data management and statistics</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$35,225.00
-------	---	---	--------------------

3.148	Nonpriority creditor's name and mailing address The Harrison Group, Inc. 3 Raymond Drive Suite 201 Havertown, PA 19083 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Board expense reimbursement</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$180.00
-------	---	---	-----------------

3.149	Nonpriority creditor's name and mailing address The O'Connor Group 418 Gulph Ridge Drive King of Prussia, PA 19406 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Temp labor/recruiting and consulting HR assistance</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$64,824.30
-------	---	--	--------------------

3.150	Nonpriority creditor's name and mailing address The Plan Advocate 150 South Warner Road Suite 300 King of Prussia, PA 19406 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>HR services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,378.44
-------	--	---	-------------------

3.151	Nonpriority creditor's name and mailing address The Protection Bureau Accounts Receivable Dept. 197 Philips Road Exton, PA 19341 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Office security services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$480.00
-------	---	--	-----------------

3.152	Nonpriority creditor's name and mailing address The University of Iowa Pharmaceuticals 115 South Grand Avenue G-20 Iowa City, IA 52242 Date(s) debt was incurred ____ Last 4 digits of account number ____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Pharmaceutical manufacturing services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,985.15
-------	---	---	-------------------

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.153	Nonpriority creditor's name and mailing address Torillo & Associates, LLC 2 Rock Hill Road Newtown Square, PA 19073 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralmmune HR consulting</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$9,350.00
-------	--	---	-------------------

3.154	Nonpriority creditor's name and mailing address TRIO 5 Sylvan Way Parsippany, NJ 07054 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Teralmmune business services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$54,924.25
-------	---	---	--------------------

3.155	Nonpriority creditor's name and mailing address Troutman Pepper Hamilton Sanders LLP 3000 Two Logan Square Eighteenth and Arch Streets Philadelphia, PA 19103-2799 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Legal services</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,297,028.67
-------	---	---	-----------------------

3.156	Nonpriority creditor's name and mailing address Trovare Preclinical Consulting, LLC PO Box 3435 Ventura, CA 93006 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>GLP studies BX 3000</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$23,975.00
-------	--	--	--------------------

3.157	Nonpriority creditor's name and mailing address University of Florida Research Foundation, Inc. 310 Walker Hall PO Box 115500 Gainesville, FL 32611-5500 Date(s) debt was incurred __ Last 4 digits of account number <u>2586</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Royalties</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$5,000.00
-------	---	--	-------------------

3.158	Nonpriority creditor's name and mailing address UPS PO Box 7247-0244 Philadelphia, PA 19170-0001 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Freight/postage</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$122.18
-------	---	--	-----------------

3.159	Nonpriority creditor's name and mailing address UPToDate, Inc. 230 Third Avenue Waltham, MA 02451 Date(s) debt was incurred __ Last 4 digits of account number __	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Software for clinicians in trials</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$673.00
-------	--	--	-----------------

Debtor	Baudax Bio, Inc. Name _____	Case number (if known)	24-10583
--------	---------------------------------------	------------------------	-----------------

3.160	Nonpriority creditor's name and mailing address Valogic 21 Byte Ct. Frederick, MD 21702 Date(s) debt was incurred _____ Last 4 digits of account number <u>7788</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>GMP advice and environment monitoring system</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$92,556.14
3.161	Nonpriority creditor's name and mailing address VenAmerica Communications, Inc. PO Box 190 Olney, MD 20830-0190 Date(s) debt was incurred _____ Last 4 digits of account number <u>1903</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Data/phone cabling and installation</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$3,709.26
3.162	Nonpriority creditor's name and mailing address Verizon PO Box 16804 Newark, NJ 07101-6804 Date(s) debt was incurred _____ Last 4 digits of account number <u>0160</u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$292.86
3.163	Nonpriority creditor's name and mailing address Verizon Wireless PO Box 408 Newark, NJ 07101-0408 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,351.68
3.164	Nonpriority creditor's name and mailing address WCG IRB, Inc. 1019 39th Avenue Suite 120 Puyallup, WA 98374 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Central IRB reviewer</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$1,005.00
3.165	Nonpriority creditor's name and mailing address William Ashton 450 Inveraray Road Villanova, PA 19085 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Director fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$43,333.33
3.166	Nonpriority creditor's name and mailing address Winston J. Churchill 500 SE Mizner Blvd. Apt. 305A Boca Raton, FL 33432-6083 Date(s) debt was incurred _____ Last 4 digits of account number _____	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Director fees</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$33,250.00

Debtor	Baudax Bio, Inc. <small>Name</small>	Case number (if known)	24-10583
--------	--	------------------------	-----------------

3.167	Nonpriority creditor's name and mailing address Wontae Chang 11976 Artery Drive Fairfax, VA 22030 Date(s) debt was incurred <u>Dec 2022</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Promissory note</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$11,833.34
-------	--	---	--------------------

3.168	Nonpriority creditor's name and mailing address WPT Land 2 LP 5 Great Valley Parkway Suite 209 Malvern, PA 19355 Date(s) debt was incurred <u> </u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Commercial rent - Malvern location - Nov, Dec, Jan</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$87,831.42
-------	---	--	--------------------

3.169	Nonpriority creditor's name and mailing address Young O. Hahm 17827 Shotley Bridge Pl. Olney, MD 20832 Date(s) debt was incurred <u>Sept 2022</u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Promissory note</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$14,400.00
-------	--	---	--------------------

3.170	Nonpriority creditor's name and mailing address Yourway Transport, Inc. 6681 Snowdrift Road Allentown, PA 18106 Date(s) debt was incurred <u> </u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Freight/postage</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$2,600.40
-------	--	---	-------------------

3.171	Nonpriority creditor's name and mailing address Zoom Video Conferencing 55 Almaden Blvd. Suite 600 San Jose, CA 95113 Date(s) debt was incurred <u> </u> Last 4 digits of account number <u> </u>	As of the petition filing date, the claim is: <i>Check all that apply.</i> <input type="checkbox"/> Contingent <input type="checkbox"/> Unliquidated <input type="checkbox"/> Disputed Basis for the claim: <u>Service provider</u> Is the claim subject to offset? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes	\$4,502.90
-------	--	--	-------------------

Part 3: List Others to Be Notified About Unsecured Claims

4. List in alphabetical order any others who must be notified for claims listed in Parts 1 and 2. Examples of entities that may be listed are collection agencies, assignees of claims listed above, and attorneys for unsecured creditors.

If no others need to be notified for the debts listed in Parts 1 and 2, do not fill out or submit this page. If additional pages are needed, copy the next page.

Name and mailing address	On which line in Part1 or Part 2 is the related creditor (if any) listed?	Last 4 digits of account number, if any
--------------------------	---	---

Part 4: Total Amounts of the Priority and Nonpriority Unsecured Claims

5. Add the amounts of priority and nonpriority unsecured claims.

	<div style="background-color: #f0f0f0; padding: 2px; border: 1px solid #ccc; display: inline-block;">Total of claim amounts</div>
5a. Total claims from Part 1	5a. \$ <u>1,630,572.11</u>
5b. Total claims from Part 2	5b. + \$ <u>10,995,246.45</u>
5c. Total of Parts 1 and 2 Lines 5a + 5b = 5c.	5c. \$ <div style="border: 1px solid black; padding: 5px; display: inline-block;">12,625,818.56</div>

Fill in this information to identify the case:

Debtor name **Baudax Bio, Inc.**

United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**

Case number (if known) **24-10583**

☐ Check if this is an amended filing

Official Form 206G

Schedule G: Executory Contracts and Unexpired Leases

12/15

Be as complete and accurate as possible. If more space is needed, copy and attach the additional page, number the entries consecutively.

1. Does the debtor have any executory contracts or unexpired leases?

☐ No. Check this box and file this form with the debtor's other schedules. There is nothing else to report on this form.

☒ Yes. Fill in all of the information below even if the contacts of leases are listed on *Schedule A/B: Assets - Real and Personal*

Property

(Official Form 206A/B).

2. List all contracts and unexpired leases

State the name and mailing address for all other parties with whom the debtor has an executory contract or unexpired lease

2.1. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

Office lease located at 20400 Century Boulevard, Suite 125, Germantown, MD 20874.

Lease term expires Dec 2031

**ARE-Maryland No. 52, LLC
Attention: Corporate Secretary
26 North Euclid Avenue
Pasadena, CA 91101**

2.2. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

License agreement for use of certain patent rights held by Cornell University

**Cornell University
Center for Technology Licensing
Attn: Executive Director
395 Pine Tree Road, Suite 310
Ithaca, NY 14850**

2.3. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

2 Toshiba Copiers

Lease term expires Dec 2024

**TGI Office Automation
120 3rd Street
Brooklyn, NY 11231**

2.4. State what the contract or lease is for and the nature of the debtor's interest

State the term remaining

List the contract number of any government contract

Lease of commerical space at 420-500 Lapp Road, Suites 480 and 490, Malvern, PA 19355. Lease term expires Dec 2027

**WPT Land 2 LP
c/o Workspace Property Trust
7 Great Valley Parkway
Suite 190
Malvern, PA 19355**

Fill in this information to identify the case:

Debtor name **Baudax Bio, Inc.**

United States Bankruptcy Court for the: **EASTERN DISTRICT OF PENNSYLVANIA**

Case number (if known) **24-10583**

☐ Check if this is an amended filing

Official Form 206H
Schedule H: Your Codebtors

12/15

Be as complete and accurate as possible. If more space is needed, copy the Additional Page, numbering the entries consecutively. Attach the Additional Page to this page.

1. Do you have any codebtors?

☐ No. Check this box and submit this form to the court with the debtor's other schedules. Nothing else needs to be reported on this form.

☒ Yes

2. In Column 1, list as codebtors all of the people or entities who are also liable for any debts listed by the debtor in the schedules of creditors, Schedules D-G. Include all guarantors and co-obligors. In Column 2, identify the creditor to whom the debt is owed and each schedule on which the creditor is listed. If the codebtor is liable on a debt to more than one creditor, list each creditor separately in Column 2.

Column 1: Codebtor

Column 2: Creditor

Name

Mailing Address

Name

Check all schedules that apply:

2.1 **Baudax Bio Limited** **490 Lapp Road Malvern, PA 19355**

MAM Eagle Lender, LLC

☒ D **2.1**
☐ E/F _____
☐ G _____

2.2 **Baudax Bio N.A. LLC** **490 Lapp Road Malvern, PA 19355**

MAM Eagle Lender, LLC

☒ D **2.1**
☐ E/F _____
☐ G _____

2.3 **Teralimmune, LLC** **20400 Century Blvd. Suite 125 Germantown, MD 20874**

MAM Eagle Lender, LLC

☒ D **2.1**
☐ E/F _____
☐ G _____

Fill in this information to identify the case:

Debtor name Baudax Bio, Inc.

United States Bankruptcy Court for the: EASTERN DISTRICT OF PENNSYLVANIA

Case number (if known) 24-10583

☐ Check if this is an amended filing

Official Form 207

Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy

04/22

The debtor must answer every question. If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and case number (if known).

Part 1: Income

1. Gross revenue from business

☐ None.

Identify the beginning and ending dates of the debtor's fiscal year, which may be a calendar year

From the beginning of the fiscal year to filing date:
From 1/01/2024 to Filing Date

Sources of revenue
Check all that apply

☒ Operating a business
☐ Other _____

Gross revenue
(before deductions and exclusions)

\$0.00

For prior year:
From 1/01/2023 to 12/31/2023

☒ Operating a business
☐ Other _____

\$0.00

For year before that:
From 1/01/2022 to 12/31/2022

☒ Operating a business
☐ Other _____

\$2,010,004.00

2. Non-business revenue

Include revenue regardless of whether that revenue is taxable. *Non-business income* may include interest, dividends, money collected from lawsuits, and royalties. List each source and the gross revenue for each separately. Do not include revenue listed in line 1.

☐ None.

Description of sources of revenue

Gross revenue from
each source
(before deductions and exclusions)

From the beginning of the fiscal year to filing date:
From 1/01/2024 to Filing Date

Terimmune equipment sales

\$225,750.00

For prior year:
From 1/01/2023 to 12/31/2023

Terimmune equipment sales

\$22,772.00

Part 2: List Certain Transfers Made Before Filing for Bankruptcy

3. Certain payments or transfers to creditors within 90 days before filing this case

List payments or transfers—including expense reimbursements—to any creditor, other than regular employee compensation, within 90 days before filing this case unless the aggregate value of all property transferred to that creditor is less than \$7,575. (This amount may be adjusted on 4/01/25 and every 3 years after that with respect to cases filed on or after the date of adjustment.)

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**☐ None.

Creditor's Name and Address	Dates	Total amount of value	Reasons for payment or transfer <i>Check all that apply</i>
-----------------------------	-------	-----------------------	--

4. Payments or other transfers of property made within 1 year before filing this case that benefited any insider

List payments or transfers, including expense reimbursements, made within 1 year before filing this case on debts owed to an insider or guaranteed or cosigned by an insider unless the aggregate value of all property transferred to or for the benefit of the insider is less than \$7,575. (This amount may be adjusted on 4/01/25 and every 3 years after that with respect to cases filed on or after the date of adjustment.) Do not include any payments listed in line 3. *Insiders* include officers, directors, and anyone in control of a corporate debtor and their relatives; general partners of a partnership debtor and their relatives; affiliates of the debtor and insiders of such affiliates; and any managing agent of the debtor. 11 U.S.C. § 101(31).

☐ None.

Insider's name and address Relationship to debtor	Dates	Total amount of value	Reasons for payment or transfer
--	-------	-----------------------	---------------------------------

5. Repossessions, foreclosures, and returns

List all property of the debtor that was obtained by a creditor within 1 year before filing this case, including property repossessed by a creditor, sold at a foreclosure sale, transferred by a deed in lieu of foreclosure, or returned to the seller. Do not include property listed in line 6.

☐ None

Creditor's name and address	Describe of the Property	Date	Value of property
-----------------------------	--------------------------	------	-------------------

6. Setoffs

List any creditor, including a bank or financial institution, that within 90 days before filing this case set off or otherwise took anything from an account of the debtor without permission or refused to make a payment at the debtor's direction from an account of the debtor because the debtor owed a debt.

☐ None

Creditor's name and address	Description of the action creditor took	Date action was taken	Amount
-----------------------------	---	-----------------------	--------

Part 3: Legal Actions or Assignments**7. Legal actions, administrative proceedings, court actions, executions, attachments, or governmental audits**

List the legal actions, proceedings, investigations, arbitrations, mediations, and audits by federal or state agencies in which the debtor was involved in any capacity—within 1 year before filing this case.

☐ None.

Case title Case number	Nature of case	Court or agency's name and address	Status of case
---------------------------	----------------	------------------------------------	----------------

8. Assignments and receivership

List any property in the hands of an assignee for the benefit of creditors during the 120 days before filing this case and any property in the hands of a receiver, custodian, or other court-appointed officer within 1 year before filing this case.

☐ None**Part 4: Certain Gifts and Charitable Contributions****9. List all gifts or charitable contributions the debtor gave to a recipient within 2 years before filing this case unless the aggregate value of the gifts to that recipient is less than \$1,000**☐ None

Recipient's name and address	Description of the gifts or contributions	Dates given	Value
------------------------------	---	-------------	-------

Part 5: Certain Losses**10. All losses from fire, theft, or other casualty within 1 year before filing this case.**

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**☒ None

Description of the property lost and how the loss occurred	Amount of payments received for the loss	Dates of loss	Value of property lost
	If you have received payments to cover the loss, for example, from insurance, government compensation, or tort liability, list the total received. List unpaid claims on Official Form 106A/B (Schedule A/B: Assets – Real and Personal Property).		

Part 6: Certain Payments or Transfers**11. Payments related to bankruptcy**

List any payments of money or other transfers of property made by the debtor or person acting on behalf of the debtor within 1 year before the filing of this case to another person or entity, including attorneys, that the debtor consulted about debt consolidation or restructuring, seeking bankruptcy relief, or filing a bankruptcy case.

☐ None.

Who was paid or who received the transfer? Address	If not money, describe any property transferred	Dates	Total amount or value
11.1. Smith Kane Holman, LLC 112 Moores Road Suite 300 Malvern, PA 19355		2/2/24	\$100,000.00
Email or website address dsmith@skhlaw.com			
Who made the payment, if not debtor?			

12. Self-settled trusts of which the debtor is a beneficiary

List any payments or transfers of property made by the debtor or a person acting on behalf of the debtor within 10 years before the filing of this case to a self-settled trust or similar device.
Do not include transfers already listed on this statement.

☒ None.

Name of trust or device	Describe any property transferred	Dates transfers were made	Total amount or value
-------------------------	-----------------------------------	---------------------------	-----------------------

13. Transfers not already listed on this statement

List any transfers of money or other property by sale, trade, or any other means made by the debtor or a person acting on behalf of the debtor within 2 years before the filing of this case to another person, other than property transferred in the ordinary course of business or financial affairs. Include both outright transfers and transfers made as security. Do not include gifts or transfers previously listed on this statement.

☐ None.

Who received transfer? Address	Description of property transferred or payments received or debts paid in exchange	Date transfer was made	Total amount or value
13.1 Alkermes Pharma Ireland Limited 900 Winter Street Waltham, MA 02451	Intellectual property rights in and other property/interests related to ANJESO.	3/29/23	\$0.00
Relationship to debtor ANJESO manufacturer and creditor			

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**

	Who received transfer? Address	Description of property transferred or payments received or debts paid in exchange	Date transfer was made	Total amount or value
13.2	Cartesian Therapeutics, Inc. 704 Quince Orchard Rd Gaithersburg, MD 20878	Small cell manufacturing unit	Jan 31, 2024	\$150,000.00
	Relationship to debtor			
13.3	Kaigene, Inc. 12358 Parklawn Dr. North Bethesda, MD 20852	Lab equipment	Dec 29, 2023	\$18,572.00
	Relationship to debtor			
13.4	Ngene Bio, Inc. Seoul, South Korea	Lab equipment	Jan 19, 2024	\$42,750.00
	Relationship to debtor			
13.5	Yoscak Associates 8628 Dakota Dr Gaithersburg, MD 20877	Office furniture	Dec 27, 2023	\$4,200.00
	Relationship to debtor			
13.6	Afab Lab Resources 260 Interstate Cir #2A Frederick, MD 21704	Lab equipment	Jan 23, 2024	\$33,000.00
	Relationship to debtor			
13.7	Aon Risk Services Central, Inc. Aon Risk Services Companies, Inc. PO Box 7247-7376 Philadelphia, PA 19170-7376	Insurance premium payments; renewal of 2024 insurance policies	Jan 26, 2024, Feb 22, 2024	\$200,000.00
	Relationship to debtor Commercial insurer			

Part 7: Previous Locations**14. Previous addresses**

List all previous addresses used by the debtor within 3 years before filing this case and the dates the addresses were used.

☐ Does not apply

Address	Dates of occupancy From-To
---------	-------------------------------

Part 8: Health Care Bankruptcies**15. Health Care bankruptcies**

Is the debtor primarily engaged in offering services and facilities for:

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**

- diagnosing or treating injury, deformity, or disease, or
- providing any surgical, psychiatric, drug treatment, or obstetric care?

- ☒ No. Go to Part 9.
- ☐ Yes. Fill in the information below.

Facility name and address

Nature of the business operation, including type of services the debtor provides

If debtor provides meals and housing, number of patients in debtor's care

Part 9: Personally Identifiable Information**16. Does the debtor collect and retain personally identifiable information of customers?**

- ☒ No.
- ☐ Yes. State the nature of the information collected and retained.

17. Within 6 years before filing this case, have any employees of the debtor been participants in any ERISA, 401(k), 403(b), or other pension or profit-sharing plan made available by the debtor as an employee benefit?

- ☐ No. Go to Part 10.
- ☒ Yes. Does the debtor serve as plan administrator?

- ☒ No Go to Part 10.
- ☐ Yes. Fill in below:

Part 10: Certain Financial Accounts, Safe Deposit Boxes, and Storage Units**18. Closed financial accounts**

Within 1 year before filing this case, were any financial accounts or instruments held in the debtor's name, or for the debtor's benefit, closed, sold, moved, or transferred?

Include checking, savings, money market, or other financial accounts; certificates of deposit; and shares in banks, credit unions, brokerage houses, cooperatives, associations, and other financial institutions.

- ☒ None

Financial Institution name and Address

Last 4 digits of account number

Type of account or instrument

Date account was closed, sold, moved, or transferred

Last balance before closing or transfer

19. Safe deposit boxes

List any safe deposit box or other depository for securities, cash, or other valuables the debtor now has or did have within 1 year before filing this case.

- ☒ None

Depository institution name and address

Names of anyone with access to it
Address

Description of the contents

Does debtor still have it?

20. Off-premises storage

List any property kept in storage units or warehouses within 1 year before filing this case. Do not include facilities that are in a part of a building in which the debtor does business.

- ☐ None

Facility name and address

Names of anyone with access to it

Description of the contents

Does debtor still have it?

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**

Facility name and address	Names of anyone with access to it	Description of the contents	Does debtor still have it?
Public Storage 49 Lancaster Ave Frazer, PA 19355	Gerri Henwood 1554 Paoli Pike, #308 West Chester, PA 19380 Christopher Sharr 1554 Paoli Pike, #308 West Chester, PA 19380	72 boxes of data on clinical studies and regulatory filings	<input type="checkbox"/> No <input checked="" type="checkbox"/> Yes

Part 11: Property the Debtor Holds or Controls That the Debtor Does Not Own**21. Property held for another**

List any property that the debtor holds or controls that another entity owns. Include any property borrowed from, being stored for, or held in trust. Do not list leased or rented property.

☒ None

Part 12: Details About Environment Information

For the purpose of Part 12, the following definitions apply:

Environmental law means any statute or governmental regulation that concerns pollution, contamination, or hazardous material, regardless of the medium affected (air, land, water, or any other medium).

Site means any location, facility, or property, including disposal sites, that the debtor now owns, operates, or utilizes or that the debtor formerly owned, operated, or utilized.

Hazardous material means anything that an environmental law defines as hazardous or toxic, or describes as a pollutant, contaminant, or a similarly harmful substance.

Report all notices, releases, and proceedings known, regardless of when they occurred.

22. Has the debtor been a party in any judicial or administrative proceeding under any environmental law? Include settlements and orders.

- ☒ No.
☐ Yes. Provide details below.

Case title Case number	Court or agency name and address	Nature of the case	Status of case
---------------------------	----------------------------------	--------------------	----------------

23. Has any governmental unit otherwise notified the debtor that the debtor may be liable or potentially liable under or in violation of an environmental law?

- ☒ No.
☐ Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
-----------------------	------------------------------------	-----------------------------	----------------

24. Has the debtor notified any governmental unit of any release of hazardous material?

- ☒ No.
☐ Yes. Provide details below.

Site name and address	Governmental unit name and address	Environmental law, if known	Date of notice
-----------------------	------------------------------------	-----------------------------	----------------

Part 13: Details About the Debtor's Business or Connections to Any Business**25. Other businesses in which the debtor has or has had an interest**

List any business for which the debtor was an owner, partner, member, or otherwise a person in control within 6 years before filing this case. Include this information even if already listed in the Schedules.

Debtor **Baudax Bio, Inc.**

Case number (if known) **24-10583**

☐ None

Business name address	Describe the nature of the business	Employer Identification number Do not include Social Security number or ITIN.
25.1. Baudax Bio, Ltd. 490 Lapp Road Malvern, PA 19355	Irish wholly owned subsidiary of the Debtor	Dates business existed EIN: Ireland company number: 562027 From-To Q4 2019 - present
25.2. Teralimmune, LLC 20400 Century Blvd. Suite 125 Germantown, MD 20874	Wholly owned subsidiary of the Debtor	EIN: 22-1146430 From-To April 2019 - present
25.3. Teralimmune Therapeutics, Co., Ltd.	South Korean partner entity in which the Debtor holds a 10% interest	EIN: From-To Aug 2022 - present
25.4. Baudax Bio N.A. LLC 490 Lapp Road Malvern, PA 19355	Wholly owned subsidiary of the Debtor	EIN: From-To Q4 2019 - present

26. **Books, records, and financial statements**

26a. List all accountants and bookkeepers who maintained the debtor's books and records within 2 years before filing this case.

☐ None

Name and address	Date of service From-To
26a.1. Richard Casten 1554 Paoli Pike #308 West Chester, PA 19380	2/22/22 - 3/31/22
26a.2. Jillian Dilmore 5 Willow Drive Malvern, PA 19355	11/2019 - 10/2023
26a.3. Nicole R. Knapp-Kerper 559 Vanderslice Street Phoenixville, PA 19460	2/2022 - 12/2023, occasional consults 2024
26a.4. Gerri Henwood 1554 Paoli Pike West Chester, PA 19380	1/2024 - present

26b. List all firms or individuals who have audited, compiled, or reviewed debtor's books of account and records or prepared a financial statement within 2 years before filing this case.

☐ None

Name and address	Date of service From-To
26b.1. KPMG Dept. 0522 PO Box 120522 Dallas, TX 75312-0522	Q4 2021 - Q2 2022, Q3 2023

Debtor **Baudax Bio, Inc.**

Case number (if known) **24-10583**

Name and address	Date of service From-To
26b.2. Eisner Amper LLP 733 Third Avenue New York, NY 10017	Q2 2022 - Q2 2023

26c. List all firms or individuals who were in possession of the debtor's books of account and records when this case is filed.

☐ None

Name and address	If any books of account and records are unavailable, explain why
26c.1. Nicole R. Knapp-Kerper 1554 Paoli Pike #308 Phoenixville, PA 19460	
26c.2. Gerri Henwood 1554 Paoli Pike #308 West Chester, PA 19380	

26d. List all financial institutions, creditors, and other parties, including mercantile and trade agencies, to whom the debtor issued a financial statement within 2 years before filing this case.

☐ None

Name and address
26d.1. MAM Eagle Lender, LLC One Bryant Park, 38th Floor New York, NY 10036

27. Inventories

Have any inventories of the debtor's property been taken within 2 years before filing this case?

☒ No

☐ Yes. Give the details about the two most recent inventories.

Name of the person who supervised the taking of the inventory	Date of inventory	The dollar amount and basis (cost, market, or other basis) of each inventory
---	-------------------	--

28. List the debtor's officers, directors, managing members, general partners, members in control, controlling shareholders, or other people in control of the debtor at the time of the filing of this case.

Name	Address	Position and nature of any interest	% of interest, if any
Cede & Co	570 Washington Boulevard Jersey City, NJ 07310	Nominal shareholder with 20% or more interest in Baudax voting securities.	46.648%
Name	Address	Position and nature of any interest	% of interest, if any
Gerri Henwood	1554 Paoli Pike #308 West Chester, PA 19380	Director, President, and CEO	
Name	Address	Position and nature of any interest	% of interest, if any
Yong Chan Kim	1554 Paoli Pike #308 West Chester, PA 19380	Director and Chief Scientific Officer	

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**

Name	Address	Position and nature of any interest	% of interest, if any
Wayne B. Weisman	1554 Paoli Pike #308 West Chester, PA 19380	Chairman of the Board of Directors	
William L. Ashton	1554 Paoli Pike #308 West Chester, PA 19380	Director	
Arnold Baskies	1554 Paoli Pike #308 West Chester, PA 19380	Director	
Winston J. Churchill	1554 Paoli Pike #308 West Chester, PA 19380	Director	
Andrew Drechsler	1554 Paoli Pike #308 West Chester, PA 19380	Director	

29. Within 1 year before the filing of this case, did the debtor have officers, directors, managing members, general partners, members in control of the debtor, or shareholders in control of the debtor who no longer hold these positions?

- ☐ No
☒ Yes. Identify below.

Name	Address	Position and nature of any interest	Period during which position or interest was held
Jillian Dilmore	1554 Paoli Pike #308 West Chester, PA 19380	Principal Accounting Officer	January 2021 - October 2023
Richard S. Casten	1554 Paoli Pike #308 West Chester, PA 19380	CFO	March 2021 - March 2022

30. **Payments, distributions, or withdrawals credited or given to insiders**

Within 1 year before filing this case, did the debtor provide an insider with value in any form, including salary, other compensation, draws, bonuses, loans, credits on loans, stock redemptions, and options exercised?

- ☐ No
☒ Yes. Identify below.

Debtor **Baudax Bio, Inc.**Case number (if known) **24-10583**

	Name and address of recipient	Amount of money or description and value of property	Dates	Reason for providing the value
30.1	Gerri Henwood 1554 Paoli Pike #308 West Chester, PA 19380	\$274,440.26	Feb 22, 2023 - Q3 2023	Salary and benefits
	Relationship to debtor Director, President and CEO			
30.2	Jillian Dilmore 1554 Paoli Pike #308 West Chester, PA 19380	\$161,110	Feb 22, 2023 - September 30, 2023	Salary and benefits
	Relationship to debtor Principal Accounting Officer			
30.3	Wayne B. Weisman 1554 Paoli Pike #308 West Chester, PA 19380	\$12,500	Q1 2023	Director and Chairman of the Board fees
	Relationship to debtor Chairman of the Board			
30.4	William Ashton 1554 Paoli Pike #308 West Chester, PA 19380	\$12,500	Q1 2023	Director and chair of committee fees
	Relationship to debtor Director			
30.5	Arnold M. Baskies, MD 1554 Paoli Pike #308 West Chester, PA 19380	\$10,000	Q1 2023	Director fees
	Relationship to debtor Director			
30.6	Winston J. Churchill 1554 Paoli Pike #308 West Chester, PA 19380	\$12,500	Q1 2023	Director and chair of committee fees
	Relationship to debtor Director			
30.7	Andrew Drechsler 1554 Paoli Pike #308 West Chester, PA 19380	\$12,500	Q1 2023	Director and chair of committee fees
	Relationship to debtor Director			

Debtor **Baudax Bio, Inc.**

Case number (if known) **24-10583**

31. Within 6 years before filing this case, has the debtor been a member of any consolidated group for tax purposes?

- ☒ No
☐ Yes. Identify below.

Name of the parent corporation

Employer Identification number of the parent corporation

32. Within 6 years before filing this case, has the debtor as an employer been responsible for contributing to a pension fund?

- ☒ No
☐ Yes. Identify below.

Name of the pension fund

Employer Identification number of the pension fund

Part 14: Signature and Declaration

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

I have examined the information in this *Statement of Financial Affairs* and any attachments and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on **March 7, 2024**

/s/ Gerri Henwood

Signature of individual signing on behalf of the debtor

Gerri Henwood

Printed name

Position or relationship to debtor **Chief Executive Officer**

Are additional pages to *Statement of Financial Affairs for Non-Individuals Filing for Bankruptcy* (Official Form 207) attached?

- ☒ No
☐ Yes

B2030 (Form 2030) (12/15)

United States Bankruptcy Court
Eastern District of Pennsylvania

In re **Baudax Bio, Inc.**

Debtor(s)

Case No. **24-10583**

Chapter **11**

DISCLOSURE OF COMPENSATION OF ATTORNEY FOR DEBTOR(S)

1. Pursuant to 11 U.S.C. § 329(a) and Fed. Bankr. P. 2016(b), I certify that I am the attorney for the above named debtor(s) and that compensation paid to me within one year before the filing of the petition in bankruptcy, or agreed to be paid to me, for services rendered or to be rendered on behalf of the debtor(s) in contemplation of or in connection with the bankruptcy case is as follows:

For legal services, I have agreed to accept	\$	100,000.00
Prior to the filing of this statement I have received	\$	100,000.00
Balance Due	\$	0.00

2. \$ **1,738.00** of the filing fee has been paid.
3. The source of the compensation paid to me was:
☒ Debtor ☐ Other (specify):
4. The source of compensation to be paid to me is:
☒ Debtor ☐ Other (specify):
5. ☒ I have not agreed to share the above-disclosed compensation with any other person unless they are members and associates of my law firm.
☐ I have agreed to share the above-disclosed compensation with a person or persons who are not members or associates of my law firm. A copy of the agreement, together with a list of the names of the people sharing in the compensation is attached.
6. In return for the above-disclosed fee, I have agreed to render legal service for all aspects of the bankruptcy case, including:
a. Analysis of the debtor's financial situation, and rendering advice to the debtor in determining whether to file a petition in bankruptcy;
b. Preparation and filing of any petition, schedules, statement of affairs and plan which may be required;
c. Representation of the debtor at the meeting of creditors and confirmation hearing, and any adjourned hearings thereof;
d. Representation of the debtor in adversary proceedings and other contested bankruptcy matters;
e. [Other provisions as needed]
7. By agreement with the debtor(s), the above-disclosed fee does not include the following service:

CERTIFICATION

I certify that the foregoing is a complete statement of any agreement or arrangement for payment to me for representation of the debtor(s) in this bankruptcy proceeding.

March 7, 2024

Date

/s/ David B. Smith

David B. Smith 59098

Signature of Attorney

Smith Kane Holman, LLC

112 Moores Road

Suite 300

Malvern, PA 19355

610-407-7215 Fax: 610-407-7218

dsmith@skhlaw.com

Name of law firm

**United States Bankruptcy Court
Eastern District of Pennsylvania**

In re **Baudax Bio, Inc.**

Debtor(s)

Case No. **24-10583**

Chapter **11**

LIST OF EQUITY SECURITY HOLDERS

Following is the list of the Debtor's equity security holders which is prepared in accordance with rule 1007(a)(3) for filing in this Chapter 11 Case

Name and last known address or place of business of holder	Security Class	Number of Securities	Kind of Interest
Alton Sports Co Ltd Kyusik Kang, 8F C-Dong, 25, Pangyo-RO 256Beon-Gil, Bundang-Gu, Seongham-SI Gyeonggi-DO 13487 South Korea	Common Stock	415,150	0.791%
Archevrosbiostar Fund-2 Hyunjung OH 14th Floor, 10 Gukjegeumyung-RO Yeongdeungpo-GU, Seoul 07326 South Korea	Common Stock	913,325	1.741%
Broadridge as Exchange Agent For teraimmune Inc. 51 Mercedes Way Brentwood, NY 11717-8368	Common Stock	4,168,423	7.946%
Broadridge as Exchange Agent for teraimmune Inc 51 Mercedes Way Brentwood, NY 11717-8368	Common Stock	186,524	0.356%
Byeungjib Choi 107-1101 136 Doanbuk-RO Seo-Gu Daejeon 35351 South Korea	Common Stock	215,878	0.412%
Byung Ha Lee 2425 McCormick Road Rockville, MD 20850	Common Stock	863,511	1.646%
Cede & Co (nominal holder o/b/o other unidentifiable shareholders) 570 Washington Boulevard Jersey City, NJ 07310	Common Stock	24,471,707	46.648% (believed to be held on behalf of other unidentifiable shareholders)
DS and Partners Jeongwoong Choi 14F One-IFC, 15, Gukjegeumyung-RO Yeongdeungpo-GU, Seoul 07335 South Korea	Common Stock	578,245	1.102%

In re: **Baudax Bio, Inc.**

Case No. **24-10583**

Debtor(s)

LIST OF EQUITY SECURITY HOLDERS

(Continuation Sheet)

Name and last known address or place of business of holder	Security Class	Number of Securities	Kind of Interest
DSC Startup Follow-On Fund II Keimin Lee 3F, 10, Ttukseom-RO 1-Gil Seongdong-Gu, Seoul 04779 South Korea	Common Stock	240,936	0.459%
DSC Tech Valueup Fund I Keimin Lee 3F, 10, Ttukseom-RO 1-Gil Seongdong-GU, Seoul 04779 South Korea	Common Stock	240,936	0.459%
Gerri Henwood 3 Jorrocks Lane Malvern, PA 19355-3327	Common Stock	15	0.000%
Jihoon Park 18919 Festival Drive Boys, MD 20841	Common Stock	1,888,931	3.601%
Kyunho Han 1711HO 111 Sinjang-RO Hanam-Si Gyeonggi-DO 12965 South Korea	Common Stock	107939	0.206%
Log-Progress-3Fund Hyobin Kim 21, Seolleung-RO 132-GIL Gangnam-GU, Seoul 06065 South Korea	Common Stock	415,155	0.791%
Medici 2018-2 Leading Enterprise Fund Munho Na 4501HO 45Floor, 511, Yeongdong-Daero Gangnam-GU Seoul 06064 South Korea	Common Stock	830,309	1.583%
Nathan Sharpe Kivisaarentie 5B 37 Helsinki 00960 Finland	Common Stock	886,462	1.690%
Panolos Bioscience Heyseong Lim #217, Dongtan-Daero 21-Gil, 10th Hwaseong-Si, Gyeonggi-Do 18471 South Korea	Common Stock	11,221	0.021%

List of equity security holders consists of 4 total page(s)

In re: **Baudax Bio, Inc.**

Case No. **24-10583**

Debtor(s)

LIST OF EQUITY SECURITY HOLDERS

(Continuation Sheet)

Name and last known address or place of business of holder	Security Class	Number of Securities	Kind of Interest
Peter Chang Whan Lee 101-502 83 Seocho-Daero 64-Gil Seocho-GU Seoul 06636 South Korea	Common Stock	79,184	0.151%
Rehoboth Investments LLC Henry Park 20 Old Tappan Road Westwood, NJ 07675	Common Stock	39,666	0.076%
Robert Edgley 16619 Cypress Bay Lane Ashton, MD 20861	Common Stock	2,886,178	5.502%
Ronald Dudek 109 Jay Drive Rockville, MD 20850-4703	Common Stock	196,762	0.375%
Sang Bum Kim 147 Seopangyo-RO Apt #1103-602 Bundang-GU, Seongnam-Si Gyeonggi-DO 13475 South Korea	Common Stock	47,148	0.090%
SCP Vitalife Partners (Israel) II L Attn: Dennis Ferry 5 Grreat Valley Parkway Suite 210 Malvern, PA 19355	Common Stock	207	0.000%
SCP Vitalife Partners II, L.P. 7 Great Valley Parkway Suite 190 Malvern, PA 19355-1446	Common Stock	620	0.001%
Seoil E&M Co Ltd Geonsu Choi 914HO, 311, Gangnam-Daero Seocho-GU, Seoul 06628 South Korea	Common Stock	103,795	0.198%
Series X Escrow (nominal holder o/b/o other unidentifiable shareholders) 490 Lapp Road Malvern, PA 19355	Common Stock	7,023,511	13.388%

In re: **Baudax Bio, Inc.**

Case No. **24-10583**

Debtor(s)

LIST OF EQUITY SECURITY HOLDERS

(Continuation Sheet)

Name and last known address or place of business of holder	Security Class	Number of Securities	Kind of Interest
Subhash Scaria & Anjala Pulickal Jt Ten 175 W Tasman Dr San Jose, CA 95134-1718	Common Stock	7	0.000%
The Bank of New York Mellon FBO Athyrium Opportunities II Acquisition LP 240 Greenwich St, #7E New York, NY 10007-2163	Common Stock	49	0.000%
Thomas Henwood 3 Jorrocks Lane Malvern, PA 19355-3327	Common Stock	14	0.000%
Turret Capital Management LP Daniel Chai 250 Park Ave, 7th Floor New York, NY 10177	Common Stock	926,119	1.765%
Yong Cham Kim 16 Chantilly Ct Rockville, MD 20850	Common Stock	4,722,326	9.002%

DECLARATION UNDER PENALTY OF PERJURY ON BEHALF OF CORPORATION OR PARTNERSHIP

I, the **Chief Executive Officer** of the corporation named as the debtor in this case, declare under penalty of perjury that I have read the foregoing List of Equity Security Holders and that it is true and correct to the best of my information and belief.

Date **March 7, 2024**

Signature **/s/ Gerri Henwood**
Gerri Henwood

*Penalty for making a false statement of concealing property: Fine of up to \$500,000 or imprisonment for up to 5 years or both.
18 U.S.C. §§ 152 and 3571.*

**United States Bankruptcy Court
Eastern District of Pennsylvania**

In re **Baudax Bio, Inc.**

Debtor(s)

Case No. **24-10583**

Chapter **11**

VERIFICATION OF CREDITOR MATRIX

I, the Chief Executive Officer of the corporation named as the debtor in this case, hereby verify that the attached list of creditors is true and correct to the best of my knowledge.

Date: **March 7, 2024**

/s/ Gerri Henwood

Gerri Henwood/Chief Executive Officer

Signer/Title